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2. SUMMARY 
 
Breast cancer is the most common malignancy among women. It is a very heterogeneous 
disease that progresses to metastasis, a usually fatal event. The cellular and biochemical 
mechanisms orchestrating this progression remain largely elusive. The characterization of the 
cellular heterogeneity of the tumor is crucial for the identification of the source of metastases, 
and elucidation of the oncogenic and tumor-suppressive networks of cancer cells is 
fundamental to the development of targeted therapies for this presently incurable disease. 
 Tumors, like normal organs, appear hierarchically organized at the cellular level. The 
concept of cancer stem cells (CSCs, a.k.a. tumor-initiating cells) has recently received 
experimental support in several human malignancies. CSCs are defined as a subpopulation of 
cells within the tumor capable of self-renewing, differentiating and recapitulating the 
heterogeneity of the original cancer, and seeding new tumors when transplanted in recipient 
animals. CSCs are thought to play important roles in the metastatic progression of breast 
cancers and to resist to classical chemo- and radiation therapies. For these reasons, the 
identification of the key signaling networks controlling CSCs is of a paramount importance 
for the development of CSC-targeted therapies.  
We demonstrate a fundamental role for protein-tyrosine phosphatase SHP2 in these 
processes in HER2-positive and triple-negative breast cancers (TNBCs), two subtypes 
associated with a poor prognosis. Knockdown of SHP2 eradicated breast CSCs in vitro and in 
xenografts, prevented invasion in 3D cultures and progression from in situ to invasive breast 
cancer in vivo, and blocked the growth of established tumors and reduced metastases. 
Mechanistically, SHP2 activated stemness-associated transcription factors including c-Myc 
and ZEB1, which resulted in the repression of let-7 miRNA and the expression of a set of 
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“SHP2 signature” genes found co-activated in a large subset of human primary breast tumors. 
Taken together, our data show that activation of SHP2 and its downstream effectors is 
required for self-renewal of breast CSCs and for tumor maintenance and progression, thus 
providing new insights into signaling cascades that regulate CSCs and a rationale for 
targeting this oncogenic PTP in breast cancer. 
Unlike the oncogenic role of SHP2 in breast cancer, we found that another member of 
the protein-tyrosine phosphatases family, PTPN12, is lost in a subset of TNBCs. Loss of 
PTPN12 activity by different means, including loss of gene expression induced by 
upregulation of miRNA-124 or inactivating mutations, promoted cellular transformation via 
activation of oncogenic receptor tyrosine kinases (RTKs) including EGFR, HER2 and 
PDGFRβ. These findings identify PTPN12 as a commonly inactivated tumor suppressor, and 
provide a rationale for combinatorially targeting proto-oncogenic tyrosine kinases in TNBC 
and other cancers based on their profile of tyrosine-phosphatase activity. 
In summary, our results identify new important targets for the treatment of aggressive 
subtypes of breast cancer. While targeting SHP2 should result in the depletion of CSCs and 
tumor regression, combined inhibition of the RTK constrained by PTPN12 in TNBCs should 
lead to major therapeutic advances for the treatment of this currently incurable disease. 
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3. INTRODUCTION 
 
Reversible tyrosine phosphorylation is an essential eukaryotic regulatory mechanism for 
numerous important aspects of cell physiology (Hunter 1987; Alonso, Sasin et al. 2004; 
Tonks 2006). This enzymatic reaction is governed by the combined action of protein-tyrosine 
kinases (PTKs) and protein-tyrosine phosphatases (PTPs) (Figure 3-1), and regulates 
important signaling cascades involved in most of cellular processes (Tonks 2006).  
 
Figure 3-1. Combined action of PTKs and PTPs governs tyrosine phosphorylation. Tyrosine 
phosphorylation is a key regulatory mechanism in eukaryotes. Proteins are phosphorylated on tyrosine residues 
by PTK and dephosphorylated by PTPs (Mustelin, Vang et al. 2005). 
 
Deregulation of the balance between PTKs and PTPs activity may result in malignant 
transformation and cancer, (Hunter 2009), and this work aimed at defining the role of two 
classical PTPs, SHP2 and PTPN12, in breast cancer.  
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3.1 Breast cancer 
 
Breast cancer is the most frequently diagnosed cancer in women (Ferlay, Autier et al. 2007; 
Jemal, Siegel et al. 2010). It is a heterogeneous disease, characterized by different molecular 
alterations driving its growth, survival and metastatic properties. Breast cancer arises from 
the epithelial cells of the mammary gland, and progresses into hyperplasia, atypical-
hyperplasia, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). The last 
and usually fatal step of breast cancer progression is metastasis, particularly frequent in 
organs like lung, bone, liver and brain (Figure 3-2) (Nguyen, Bos et al. 2009). Notably, this 
linear progression model has been challenged by several studies showing a “parallel 
progression” of breast cancer, where the metastatic cells quit the primary tumor site as early 
as DCIS (Klein 2009). 
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Figure 3-2. Breast cancer linear progression model. Schematic of breast cancer progression steps starting 
from hyperplasia and progressing into atypical hyperplasia, DCIS, Invasive carcinoma and metastasis (adapted 
from www.breastcancer.org).  
 
Currently, classification of breast cancers depends on clinical parameters (e.g., age, 
node status, tumor size, histological grade) and detection of pathological markers like the 
hormone receptors (HR) estrogen receptor (ER) and progesterone receptor (PR), and the 
tyrosine kinase receptor c-erbB2/HER2 (Perou, Sorlie et al. 2000; Di Cosimo and Baselga 
2010). However, the complexity of breast cancer is not sufficiently recapitulated by these 
markers. Genome-wide gene-expression profiles identified six breast cancer subgroups: 
luminal A, luminal B, normal-like, HER2-enriched, basal-like and claudin-low (Perou, Sorlie 
et al. 2000; Sorlie, Perou et al. 2001; Carey, Perou et al. 2006; Prat, Parker et al. 2010). Each 
of these subtypes is associated with a different prognosis, mainly influenced by intrinsic 
aggressiveness of the tumor and current therapeutic options. Basal-like, claudin-low and 
HER2-enriched breast tumors correlate with the worst prognosis (Perou, Sorlie et al. 2000; 
Sorlie, Perou et al. 2001; Carey, Perou et al. 2006; Prat, Parker et al. 2010). 
 
3.2 Luminal A and luminal B breast cancer 
 
Luminal tumors are characterized by the expression of ER, with or without co-expression of 
PR (Sims, Howell et al. 2007) and account for ~60 % of all breast cancers. In particular, 
luminal A tumors generally express both ER and PR, while the expression of these HRs is 
more variable in tumors of the luminal B subtype (Sims, Howell et al. 2007). For this reason, 
patients bearing luminal A tumors are more responsive to hormonal therapy and survive 
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longer than patients with luminal B tumors (Vargo-Gogola and Rosen 2007). In addition to 
ER and PR, luminal tumors are characterized by overexpression of other luminal markers like 
GATA3, X-box binding protein 1 and LIV-1 (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 
2001).        
The gold standard for treatment of HR-positive breast cancer has been, for over three 
decades, the ER antagonist tamoxifen. More recently, aromatase inhibitors (AIs), preventing 
the synthesis of estrogens in the peripheral tissues including breast, have been shown to be 
more effective compared to tamoxifen in post-menopausal women with early-stage and 
advanced breast cancer (Thurlimann, Keshaviah et al. 2005; Mauri, Pavlidis et al. 2006; 
Forbes, Cuzick et al. 2008). Despite these advances in the therapy of HR-positive breast 
tumors, primary and acquired resistance to endocrine therapy remain a challenge. Resistance 
mechanisms can occur as a result of the cross-talk between ERs and RTKs or with signaling 
pathways that function downstream of these receptors, such as the phosphatidylinositol 3-
kinase (PI3K)/Akt/mTOR pathway (Prat and Baselga 2008; Creighton, Fu et al. 2010; Meyer 
and Bentires-Alj 2010; Miller, Hennessy et al. 2010).  
 
3.3 HER2-enriched breast cancer 
 
Another molecular subtype of breast cancer is the HER2-enriched subtype. It accounts for 
~20% of patients and it is associated with aggressive disease and decreased survival (Slamon, 
Clark et al. 1987). In addition to HER2 activation, this subtype is characterized by 
overexpression of GRB7, TGFβ1-induced anti-apoptotic factor 1 and TNF receptor-
associated factor 4. Notably, nearly two-thirds of the HER2-enriched breast tumors bear a 
gene amplification and overexpression of HER2, while one-third of these tumors express 
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HER2 at a normal level, indicating that mechanisms other than HER2 amplification drive this 
subtype; these mechanisms may include HER2 hyperphosphorylation. 
Trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of 
HER2, improves the survival of patients with HER2-positive advanced and early-stage breast 
cancer (Lewis Phillips, Li et al. 2008). Notably, other therapeutic agents have shown 
encouraging anti-tumor activity in vivo and in early clinical studies, these include lapatinib (a 
dual HER1 and HER2 tyrosine kinase inhibitor), the humanized monoclonal antibody 
pertuzumab (which prevents HER2 dimerization by sterically preventing its paring with other 
members of the HER receptor family), the trastuzumab-DM1 complex (consisting of 
trastuzumab conjugated to the anti-microtubule agent DM1) and inhibitors of heat shock 
protein 90 (a.k.a. HSP90, a molecular chaperone required to maintain HER2 integrity and 
function) (Agus, Akita et al. 2002; Mendoza, Phillips et al. 2002; Modi, Stopeck et al. 2007; 
Lewis Phillips, Li et al. 2008; Portera, Walshe et al. 2008; Baselga and Swain 2009; von 
Minckwitz, du Bois et al. 2009; Baselga, Gelmon et al. 2010). Despite the clinical efficacy of 
HER2-targeting agents, one third of HER2-positive tumors do not respond to therapy. In 
addition, nearly half of the patients who initially respond to HER2-targeted agents will 
relapse within a year (Nagata, Lan et al. 2004).  
 
3.4 Triple-negative breast cancer 
 
Triple-negative breast cancer (TNBC), which accounts for ~20% of cases, is characterized by 
the lack of expression of ER, PR and lack of HER2 amplification. TNBCs are divided into 
basal-like and claudin-low subtypes, which share some common features like low expression 
of luminal gene clusters and luminal cytokeratins (CKs) 8 and 18. In addition, the basal-like 
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tumors are further characterized by high expression of the basal CKs 5, 14 and 17, while the 
claudin-low tumors are more enriched in epithelial-to-mesenchymal transition (EMT) 
features including loss of E-cadherin, Claudin3, 4 and 7, immune system responses and stem 
cell-associated biological processes (Sims, Howell et al. 2007; Prat, Parker et al. 2010).  
After an initial “dark-phase”, characterized by lack of specific targets, increasing 
knowledge of the biology of TNBC biology has led to clinical trials using new promising 
therapies such as EGFR targeted agents, anti-angiogenic factors and poly (ADP-ribose) 
polymerase (PARP) inhibitors (Anders and Carey 2008; Di Cosimo and Baselga 2010), some 
of which are currently in clinical trials. Given that the claudin-low subtype shows important 
features of breast cancers stem cells (Creighton, Li et al. 2009; Hennessy, Gonzalez-Angulo 
et al. 2009), agents tailored towards depletion of CSCs should be particularly effective in this 
subtype. 
 
3.5 Breast cancer stem cells 
 
The concept of cancer stem cells (CSCs, a.k.a. tumor-initiating cells), proposed by Pierce and 
colleagues in 1988 (Pierce and Speers 1988), has recently received experimental support in 
several human cancers including acute myeloid leukemia, cancers of breast, brain, pancreas, 
colon, liver and melanoma (Bonnet and Dick 1997; Al-Hajj, Wicha et al. 2003; Singh, 
Hawkins et al. 2004; Li, Heidt et al. 2007; O'Brien, Pollett et al. 2007; Ricci-Vitiani, 
Lombardi et al. 2007; Schatton, Murphy et al. 2008; Yang, Ho et al. 2008). CSCs are cells 
within a tumor which can self-renew, differentiate, and give rise to a tumor when transplanted 
into recipient mice. Unfortunately, most current cancer therapies are not tailored towards 
depleting CSCs. Indeed, most current cancer chemotherapeutic agents have been developed 
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based on their ability to decrease primary tumor size rather than specifically eliminating 
CSCs. This may explain why, in many solid malignancies including breast cancer, tumor 
regression does not necessarily translate into increased patient survival. Possible reasons for 
the failure of current therapeutic agents in the treatment of breast cancer include the 
suggested inherent drug resistance of CSCs and their propensity to reach distant organs and 
seed metastases (Dean, Fojo et al. 2005; Li, Tiede et al. 2007; Li, Lewis et al. 2008; Diehn, 
Cho et al. 2009). The concept of CSCs is developing rapidly, and it yet has not been 
unanimously accepted by the scientific community. Indeed, an attitude of healthy caution 
seems to be developing in the maturing CSC community (Clevers 2011). Unfortunately, stem 
cells and the cellular hierarchy are poorly characterized in most tissues that develop solid 
cancers. As a consequence, few if any definitive stem cell markers are available for isolating 
CSC from solid tumors. Markers for identifying CSCs are different across different tumor 
types and even among different subtypes of the same tumor. Current CSC markers are 
primarily chosen as robust, heterogeneously expressed FACS markers that allow the sorting 
of marker-positive and marker-negative populations (e.g. CD133high population in melanoma 
or CD44high/CD24low population in breast cancer). However, they are not selected on the basis 
of a deep understanding of the underlying stem cell biology of the pertinent tissue from 
which the cancer originates (Clevers 2011). In addition, the stability of the CSC phenotype 
has not yet been experimentally probed. In their study on melanoma, Morrison and 
colleagues (Quintana, Shackleton et al. 2008; Shackleton, Quintana et al. 2009) showed that 
tumors arising both from CD133− cells and from CD133+ cells sorted from an original 
melanoma re-establish the original ratios of CD133− and CD133+ cells. This experiment 
indicated that individual cancer cells can recapitulate the marker heterogeneity of the tumors 
from which they derive. Similarly, Vonderhaar and colleagues showed that the breast CSC 
markers CD44high/CD24low are under dynamic regulation in vitro and in vivo; particularly, 
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they demonstrated that non-invasive, epithelial-like CD44high/CD24high cells gave rise to 
invasive, mesenchymal CD44high/CD24low progeny (Meyer, Fleming et al. 2009). Plasticity of 
the CSC state should then be given serious consideration. Therefore, agents targeting both 
CSCs and the bulk of the tumor will most likely be needed for curing breast cancer.  
Potential approaches are to directly kill CSCs or to induce their differentiation by 
inhibiting their survival mechanisms or blocking their self-renewal (Zhou, Zhang et al. 2009). 
Alternatively, it is conceivable that interfering with the stem cell niche would also lead to 
differentiation or death of CSCs (Figure 3-3). Therefore, the identification of the signaling 
networks that control CSCs is very important for the development of novel therapeutic 
strategies. 
 
 
 
Figure 3-3. Therapeutic strategies to target CSCs. Shown are possible strategies to eradicate CSCs (Zhou, 
Zhang et al. 2009).  
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3.6 The family of classical PTPs 
 
Tyrosine phosphorylation plays a pivotal role in virtually all signaling pathways and 
biological processes mentioned above. Although PTPs were initially thought to act 
exclusively as tumor suppressors, it is now clear that they can have either inhibitory or 
stimulatory effects on cancer-associated signaling processes. A better understanding of the 
mechanisms regulating and regulated by PTPs can lead to the development of new 
pharmacological targets for breast cancer.  
 The human genome encodes ~90 PTKs and ~107 PTPs (Robinson, Wu et al. 2000; 
Alonso, Sasin et al. 2004; Julien, Dube et al. 2011), suggesting similar levels of substrate 
specificity between these two families of enzymes. PTPs are defined by the catalytic-site 
motif HC(X)5R, in which the cysteine residue functions as a nucleophile and is essential for 
catalysis. This cysteine forms the base of the active-site cleft and recognizes the phosphate of 
the target substrate. Catalysis proceeds through a two-step mechanism that involves the 
production of a cysteinyl-phosphate intermediate. In the first step, there is nucleophilic attack 
on the phosphate by the sulfur atom of the thiolate ion of the essential cysteine residue. This 
is coupled with protonation of the tyrosyl leaving group of the substrate by the conserved 
aspartic acid residue. The second step involves the hydrolysis of the phosphoenzyme 
intermediate, mediated by a glutamine residue, which coordinates a water molecule, and 
aspartic acid, which now functions as a general base, culminating in the release of phosphate 
(Figure 3-4). 
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Figure 3-4. Mechanism of action of PTPs. Shown is a schematic representation of the two-step mechanism of 
action of PTPs (Tonks 2003).  
 
In humans, the ~107 PTPs are divided in 2 groups, classical and dual specificity 
PTPs. The sub-group of “classical PTPs” comprises 37 PTP members, characterized by 
specificity for phosphotyrosine residues. Classical PTPs are subdivided into two groups, 
“transmembrane” and “non-transmembrane” PTPs (Figure 3-5) (Andersen, Mortensen et al. 
2001).  
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Figure 3-5. The family of classical PTPs. Classical PTPs can be categorized as transmembrane or non-
transmembrane proteins (Tonks 2006). 
 
The transmembrane PTPs contain a single-pass transmembrane domain, a variable 
extracellular domain responsible for cell-to-cell, cell-to-matrix or cell-to-ligand interactions, 
and an intracellular portion usually containing two tandem catalytically-active domains (with 
most of the catalytic activity residing in the membrane-proximal domain and with the 
membrane-distal domain also involved in protein-protein interaction and PTP dimerization) 
(Streuli, Krueger et al. 1990; Felberg and Johnson 1998). The non-transmembrane PTPs have 
remarkable structural diversity among each other and contain regulatory sequences that target 
them to specific subcellular locations or enable their binding to specific proteins (Figure 3-5) 
(Mauro and Dixon 1994). These regulatory sequences control the activity of the enzyme 
either directly by interaction with the active site or by controlling substrate specificity 
(Garton, Burnham et al. 1997; Pulido, Zuniga et al. 1998; Ostman, Hellberg et al. 2006).      
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3.7 Regulation of classical PTPs 
 
The activity of PTPs is tightly regulated in vivo to maintain physiological tyrosine 
phosphorylation levels. PTPs function can be regulated by different means including the 
control of gene expression, protein localization and by the post-transcriptional modifications 
listed below.   
 First, PTPs can be regulated by reversible oxidation (Meng, Fukada et al. 2002; 
Meng, Buckley et al. 2004; Persson, Sjoblom et al. 2004; Kamata, Honda et al. 2005). The 
catalytic-site motif of PTPs contains an invariant cysteine residue which is characterized by 
an extremely low pKa (den Hertog, Groen et al. 2005; Salmeen and Barford 2005; Tonks 
2005). At neutral pH this cysteine residue is present as a thiolate ion, which promotes its 
function as a nucleophile in catalysis but also renders it highly susceptible to oxidation, 
resulting in abrogation of nucleophilic function and inhibition of PTP activity. Therefore, the 
production of reactive oxygen species (ROS) can be a potent and specific mechanism of 
regulation of PTPs activity (Finkel 2003; Tonks 2005). Importantly, the oxidation of the 
catalytic cysteine is reversible, making this modification a dynamic mode of PTP regulation 
(see Figure 3-4) (Salmeen, Andersen et al. 2003).   
Second, PTPs can be regulated through phosphorylation, nitrosylation and/or 
sumoylation. For example, tyrosine-phosphorylation of PTP1B, SHP1, SHP2 and PTPα or 
serine-phosphorylation of PTPN12 affects their phosphatase activity as well as their affinity 
to substrates and interacting partners (Bennett, Tang et al. 1994; den Hertog, Tracy et al. 
1994; Garton and Tonks 1994; Dadke, Kusari et al. 2001). In addition, PTP1B was found to 
be sumoylated in response to insulin leading to a decrease in its catalytic activity (Dadke, 
Cotteret et al. 2007). 
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Third, PTPs can be regulated by proteolytic cleavage. Calcium is a critical initiator of 
protease activity and the calcium-activated protease calpain has been shown to cleave 
regulatory domains of several PTPs. For example, the non-transmembrane PTP1B, PTP-
MEG1 and SHP1 are activated upon calpain-induced cleavage (Frangioni, Oda et al. 1993; 
Gu and Majerus 1996; Falet, Pain et al. 1998). Transmembrane PTPs like LAR, PTPκ and 
PTPµ are also subject to proteolysis as a mechanism of regulation of their catalytic activity 
(Streuli, Krueger et al. 1992; Anders, Mertins et al. 2006; Ruhe, Streit et al. 2006).       
Fourth, transmembrane PTPs can be regulated via dimerization and/or binding to 
ligands. Using PTPα as a model, it was proposed that homodimerization reduced its catalytic 
activity by reciprocal occlusion of the active sites (Bilwes, den Hertog et al. 1996), although 
this regulatory mechanism does not seem to be a common feature of all transmembrane PTPs 
(Nam, Poy et al. 1999; Nam, Poy et al. 2005). In addition, extracellular ligand binding is also 
a regulatory mechanism for PTPs. For example, while PTPζ activity is reduced upon binding 
to its ligand pleiotrophin (Meng, Rodriguez-Pena et al. 2000), LAR activity appears to be 
regulated by binding to different heparan sulphate proteoglycans at synapses (Fox and Zinn 
2005; Johnson, Tenney et al. 2006) (Figure 3-6).    
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Figure 3-6. Regulation of the function of transmembrane PTPs by ligands. Shown are examples of PTPs 
regulation mechanisms via interaction with extracellular ligands. a) The binding of Pleiotrophin to the 
transmembrane PTPζ reduces its activity. b) The activity of LAR is regulated by binding to different heparan 
sulphate proteoglycans (Tonks 2006). 
    
 
3.8 Function and regulation of the oncogenic tyrosine phosphatase SHP2 
 
The Src homology-2 domain-containing phosphatase SHP2 (encoded by PTPN11), a 
ubiquitously expressed PTP, transduces mitogenic, pro-survival, pro-migratory signals from 
almost all growth factor-, cytokine- and extracellular matrix receptors. SHP2 null-embryos 
die peri-implantation and fail to yield trophoblast stem cell lines (Yang, Klaman et al. 2006). 
While SHP2 deficiency increases self-renewal of murine and human embryonic stem cells 
(Burdon, Stracey et al. 1999; Wu, Pang et al. 2009), it decreases self-renewal in neural 
stem/progenitor cells and hematopoietic stem cells (HSC), suggesting a cell-type specific role 
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of SHP2 in regulating cell fate (Chan, Li et al. 2006; Ke, Zhang et al. 2007; Zhu, Ji et al. 
2011). 
SHP2 contains two SRC homology 2 (SH2) domains (N-SH2 and C-SH2), a PTP 
domain and a C-terminal tail with a proline-rich motif and two tyrosyl phosphorylation sites 
(Y542 and Y580). In the absence of upstream stimulation, SHP2 is kept in an inactive state 
by interaction of the N-terminal SH2 domain with the PTP domain. Upon activation of RTKs, 
binding and phosphorylation of scaffolding adaptors, SHP2 binds tyrosine phosphorylated 
residues via its SH2 domains. SHP2 can also bind directly to phosphorylated tyrosine 
residues on RTKs. Binding causes a conformational change in SHP2, resulting in SHP2 
activation and dephosphorylation of its substrates. (Figure 3-7) (Chan, Kalaitzidis et al. 
2008). 
Gain-of-function (GOF) germline PTPN11 mutations were found in about half of 
patients with Noonan syndrome (NS), a common autosomal dominant developmental 
disorder (Tartaglia, Mehler et al. 2001). Moreover, GOF somatic mutations were identified in 
~34% of patients with juvenile myelomonocytic leukemia (JMML), ~6% of patients with 
acute myeloid leukemia (AML), more rarely in solid tumors but not in breast cancer 
(Tartaglia, Niemeyer et al. 2003; Bentires-Alj, Paez et al. 2004; Loh, Vattikuti et al. 2004). 
Interestingly, these GOF mutations lead to the activation of key oncogenic signaling cascades 
including ERK and AKT pathways (Wang, Yu et al. 2009). In addition to GOF mutations, 
SHP2 can be activated by different means, for example by binding to scaffolding adaptor like 
GAB2, downstream of constitutive active forms of EGFR and fibroblast growth factor 
receptor 3 (FGFR3), upon BCR-ABL activation, and downstream of active RTKs RET and 
HER2 (Sattler, Mohi et al. 2002; Agazie, Movilla et al. 2003; D'Alessio, Califano et al. 2003; 
Zhan and O'Rourke 2004; Bentires-Alj, Gil et al. 2006). SHP2 has also been found to be a 
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mediator of Helicobacter pylori-induced transformation of gastric epithelial cells via 
interaction with the CagA protein, a virulence factor secreted by H. pylori (Hatakeyama 
2004).  
  
 
 Figure 3-7. Mechanisms of SHP2 activation. Schematic of the mechanism of activation of wild-type and 
mutated SHP2. a) In absence of upstream stimulation, SHP2 is kept in an inactive state by the interaction of the 
N-terminal SH2 domain with the catalytic PTP domain. Upon activation of surface receptors, SHP2 binds 
phospho-tyrosine sites via its SH2 domains. This causes a conformational change which leads to an increase of 
the enzymatic activity of SHP2 and activation of the downstream signaling. b) In Leukemia, mutations of SHP2 
lead to permanent changes in its structure and activation of the PTP domain, causing an increased and sustained 
activation of downstream pathways (Ostman, Hellberg et al. 2006).  
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3.9 Other oncogenic PTPs in breast cancer 
 
Other PTPs have been associated with a potential oncogenic role in breast cancer, like PTP1B 
(Wiener, Kerns et al. 1994; Bjorge, Pang et al. 2000; Bentires-Alj and Neel 2007; Julien, 
Dube et al. 2007; Cortesio, Chan et al. 2008; Arias-Romero, Saha et al. 2009; Blanquart, 
Karouri et al. 2009; Johnson, Peck et al. 2010), PTPα (Ardini, Agresti et al. 2000; Zheng, 
Resnick et al. 2008), PTPε (Elson 1999; Gil-Henn and Elson 2003), LAR (Yang, Zhang et al. 
1999; Levea, McGary et al. 2000) and PTPH1 (Zhi, Hou et al. 2010). However, definitive 
evidence for their relevance for human breast cancer is still missing. Clearly, additional 
validation is required before establishing any of these PTPs as drug targets. 
 The non-transmembrane PTP1B (encoded by PTPN1), an important regulator of 
mammalian metabolism (Elchebly, Payette et al. 1999), has been linked to breast cancer. 
Mice lacking PTP1B in all tissues are hypersensitive to insulin, lean, and resistant to high fat 
diet-induced obesity (Elchebly, Payette et al. 1999; Klaman, Boss et al. 2000). 
Overexpression of PTP1B was observed in human breast tumors, with a strong association 
with HER2-positive tumors (Wiener, Kerns et al. 1994). In line with this finding, PTP1B was 
later found to be required for HER2/Neu-evoked mammary tumorigenesis (Bentires-Alj and 
Neel 2007; Julien, Dube et al. 2007). In contrast, PTP1B deficiency had no effect on polyoma 
middle T mediated tumorigenesis (Bentires-Alj and Neel 2007). Subsequently, PTP1B has 
also been associated with breast cancer cell transformation, proliferation, invadopodia 
dynamics, invasion and resistance to 4-OH tamoxifen treatment (Cortesio, Chan et al. 2008; 
Arias-Romero, Saha et al. 2009; Blanquart, Karouri et al. 2009). Mechanistically, PTP1B was 
shown to dephosphorylate and activate c-Src in human breast cancer cell lines in vitro 
(Bjorge, Pang et al. 2000; Cortesio, Chan et al. 2008; Arias-Romero, Saha et al. 2009) and to 
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suppress prolactin-mediated activation of STAT5 in breast cancer cells through inhibitory 
dephosphorylation of the STAT5 tyrosine kinase JAK2 (Johnson, Peck et al. 2010). Recent 
data from our lab show that PTP1B deletion in the mammary epithelium delays MMTV-
HER2/NeuNT-induced breast cancer (Balavenkatraman et al., submitted). In contrast, 
depletion of PTP1B after breast tumor development did not block tumor progression 
(Balavenkatraman et al., submitted). These data raise the possibility that PTP1B inhibitors 
could be used for preventing breast cancer, but not for the treatment of advanced stages of 
this disease.  
 The transmembrane PTPα is a widely expressed enzyme enriched in brain tissues 
(Skelton, Ponniah et al. 2003). Full-body PTPα knockout mice show deficits in learning, 
locomotor activity and anxiety (Skelton, Ponniah et al. 2003).  Protein levels of PTPα 
(encoded by PTPRA) were found to vary widely among breast tumors, with ~30% of cases 
manifesting significant overexpression. High PTPα levels correlated significantly with low 
tumor grade and positive estrogen receptor status (Ardini, Agresti et al. 2000). In another 
study, suppression of PTPα in breast cancer cell lines resulted in reduction of Src activity 
(Zheng, Resnick et al. 2008). Consistently, Src and PTPα depletion induced apoptosis in ER-
negative breast cancer cells (Zheng, Resnick et al. 2008), suggesting that this PTP contributes 
to the activation of oncogenic pathways. 
 The transmembrane PTPε (encoded by PTPRE) has been found upregulated in 
MMTV-RAS and MMTV-Neu tumors, suggesting that this phosphatase may play a role in 
transformation by these two oncogenes (Elson and Leder 1995). Multiparous MMTV-PTPε 
female mice, uniformly developed mammary hyperplasia accompanied by residual milk 
production and formation of sporadic tumors. The sporadic nature of these tumors, the long 
latency period and low levels of transgene expression indicated that PTPε provided a 
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necessary, but insufficient, signal for oncogenesis (Elson 1999). In addition, PTPε was shown 
to activate Src and support the transformed phenotype of Neu-induced mammary tumors 
(Gil-Henn and Elson 2003).     
 The leukocyte common antigen-related (LAR) PTP (encoded by PTPRF) is a 
prototype member of the class of transmembrane PTPs containing cell adhesion domains. 
Transgenic mice deficient in LAR exhibit defects in glucose homeostasis (Ren, Li et al. 
1998). LAR mRNA and protein levels have been found increased in breast cancer tissues 
(Yang, Zhang et al. 1999). Moreover, LAR expression in human breast cancer specimens has 
been associated with metastatic potential and ER expression (Levea, McGary et al. 2000), but 
additional studies are required to understand the importance of this phosphatase in breast 
cancer. 
 The non-transmembrane PTPH1 (encoded by PTPN3) was shown to be overexpressed 
in some metastatic human primary breast tumor (Zhi, Hou et al. 2010). Mechanistically, 
PTPH1 promotes breast cancer growth via its effect on the expression of nuclear vitamin D 
receptor (VDR) protein. Notably, this effect is independent of its phosphatase activity, but 
dependent on its ability to increase cytoplasmic translocation of VDR, leading to the mutual 
stabilization of VDR and PTPH1 (Zhi, Hou et al. 2010). 
 In summary, in vitro and in some cases in vivo data suggest an oncogenic role for 
PTP1B, PTPα, PTPε, LAR and PTPH1 in breast cancer. These observations warrant future 
experiments to demonstrate the value of each of these phosphatases as therapeutic targets in 
breast cancer.       
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3.10 Function and regulation of the tumor suppressor phosphatase PTPN12  
 
Since their discovery, PTPs have been considered potential tumor suppressor because of their 
antagonistic effects on oncogenic PTK signaling (Hunter 2009).  
PTPN12 (a.k.a. PTP-PEST) is a ubiquitously expressed PTP that plays a role in cell 
motility, cytokinesis, and apoptosis (Angers-Loustau, Cote et al. 1999; Garton and Tonks 
1999; Cousin and Alfandari 2004; Playford, Lyons et al. 2006; Sastry, Rajfur et al. 2006; 
Halle, Liu et al. 2007). In fibroblasts, PTPN12 acts downstream of integrins and receptor 
tyrosine kinases (Charest, Wagner et al. 1997; Cong, Spencer et al. 2000; Lyons, Dunty et al. 
2001) to regulate motility through its action on Rho GTPases (Sahai and Marshall 2002; 
Sastry, Lyons et al. 2002). Excess levels of PTPN12 suppress Rac1 activity while decreased 
PTPN12 levels elevate Rac1 and block RhoA activation (Sahai and Marshall 2002; Sastry, 
Lyons et al. 2002). Importantly, PTPN12 acts, either directly or indirectly, on several tyrosine 
kinases including c-SRC, c-ABL, and FAK, whose activities contribute to regulation of cell-
cell junctions and Rho GTPases (Playford, Vadali et al. 2008; Chellaiah and Schaller 2009; 
Zheng, Xia et al. 2009). Although the precise function of PTPN12 in epithelial cells has not 
been determined, few studies implicate this phosphatase in the control of intestinal 
(Takekawa, Itoh et al. 1994) and pancreatic cancer cell motility (Sirois, Cote et al. 2006) 
through c-SRC or c-ABL-dependent pathways, respectively. In mammary epithelial cells, 
PTPN12 was shown to downregulate prolactin signaling in response to EGF (Horsch, 
Schaller et al. 2001). 
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3.11 Other tumor suppressor PTPs in breast cancer  
 
Other PTPs have been suggested as tumor suppressor in breast cancer, like PTPγ 
(Panagopoulos, Pandis et al. 1996; Zheng, Kulp et al. 2000; Liu, Sugimoto et al. 2002; Liu, 
Sugimoto et al. 2004; Wang, Huang et al. 2006; Shu, Sugimoto et al. 2010), PTP-BAS 
(Bompard, Puech et al. 2002; Freiss, Bompard et al. 2004; Dromard, Bompard et al. 2007; 
Revillion, Puech et al. 2009; Glondu-Lassis, Dromard et al. 2010), MEG2 (Yuan, Wang et 
al.), GLEPP1 (Ramaswamy, Majumder et al. 2009) and PTPζ (Perez-Pinera, Garcia-Suarez et 
al. 2007). 
 The expression of the transmembrane PTPγ (encoded by PTPRG) is reduced in breast 
cancer compared to normal breast (Panagopoulos, Pandis et al. 1996; Zheng, Kulp et al. 
2000). Interestingly, the expression of this phosphatase appears to be regulated by estrogen or 
by conjugated linoleic acid (Zheng, Kulp et al. 2000; Liu, Sugimoto et al. 2002; Wang, 
Huang et al. 2006). Moreover, PTPγ overexpression was shown to inhibit growth in 
monolayer cultures, anchorage-independent growth, and tumorigenicity of MCF7 breast 
cancer cells (Liu, Sugimoto et al. 2004; Shu, Sugimoto et al. 2010). Mechanistically, 
overexpression of PTPγ in MCF7 cells reduces ERK1/2 phosphorylation and increases the 
expression of p21(cip) and p27(kip) (Shu, Sugimoto et al. 2010). These data suggest that 
PTPγ is a potential tumor suppressor, however this possibility needs to be tested in additional 
breast cancer models. 
 The non-transmembrane PTP-BAS (encoded by PTPN13) was initially found to 
promote apoptosis following tamoxifen treatment in MCF7 breast cancer cells via direct 
dephosphorylation of insulin receptor substrate-1 (IRS-1) and consequent inhibition of the 
PI3K/AKT pathway (Bompard, Puech et al. 2002; Dromard, Bompard et al. 2007). Moreover, 
PTP-BAS expression is a prognostic indicator of favorable outcome for patients with breast 
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cancer (Revillion, Puech et al. 2009). Notably, PTP-BAS expression was found decreased in 
breast cancer and metastasis specimens when compared with nonmalignant tissue (Glondu-
Lassis, Dromard et al. 2010). Depletion of PTP-BAS in MCF7 cells drastically increased 
tumor growth and invasion (Glondu-Lassis, Dromard et al. 2010). Substrate-trapping 
experiments revealed that PTP-BAS directly dephosphorylated Src on tyrosine 419, leading 
to the inactivation of the Src downstream substrates FAK and p130cas (Glondu-Lassis, 
Dromard et al. 2010), and identifying a new mechanisms by which this phosphatase inhibits 
breast tumor aggressiveness.   
 The non-transmembrane tyrosine phosphatase MEG2 (encoded by PTPN9) was 
recently shown to directly dephosphorylate and inactivate both EGFR and HER2, and 
subsequently to impair EGF-induced STAT3 and STAT5 activation, resulting in an inhibition 
of cell growth in soft agar (Yuan, Wang et al. 2010). MEG2 overexpression also reduced 
invasion and MMP2 expression in MDA-MB-231 breast cancer cells (Yuan, Wang et al. 
2010), suggesting that MEG2 plays a signal-attenuating role in breast cancer. 
 The transmembrane PTP GLEPP1 (encoded by PTPRO) is particularly expressed on 
the apical cell surface of the glomerular podocyte, and was shown to regulate the glomerular 
pressure/filtration rate relationship through an effect on podocyte structure and function 
(Wharram, Goyal et al. 2000). Expression of GLEPP1 was found to be reduced in breast 
cancer cell lines due to promoter methylation compared to normal mammary epithelial cells 
(Ramaswamy, Majumder et al. 2009). In line with this observation, treatment with 5-
azacytidine restored expression of GLEPP1. Moreover, PTPRO promoter region harbors 
estrogen-responsive elements and treatment with estrogen reduces its expression, while 
treatment with tamoxifen increases it (Ramaswamy, Majumder et al. 2009). Accordingly, 
ectopic expression of GLEPP1 sensitized cells to the growth-suppressive effects of 
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tamoxifen, indicating that this PTP might act as a tumor-suppressor (Ramaswamy, Majumder 
et al. 2009). 
 The transmembrane PTPζ (encoded by PTPRZ1) functions as a receptor for the 
cytokine pleiotrophin (PTN). PTN binding inactivates PTPζ, leading to increased tyrosine 
phosphorylation of different proteins including beta-catenin, Fyn, P190RhoGAP and ALK 
(Perez-Pinera, Garcia-Suarez et al. 2007). PTPζ was found expressed in different breast 
cancer subtypes and it correlated with ALK expression (Perez-Pinera, Garcia-Suarez et al. 
2007), a RTK with oncogenic activity (Pulford, Morris et al. 2004; Perez-Pinera, Chang et al. 
2007). This suggests that inactivation of PTPζ could activate ALK in breast cancer, and that 
suppression of this PTP may favor breast tumor growth.        
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4. RATIONALE OF THE WORK 
 
Targeted therapies for breast cancer are currently available and generally consist of endocrine 
treatment for ER-positive luminal tumors, and trastuzumab in combination with 
chemotherapy for HER2-overexpressing tumors. However, despite an initial benefit due to 
the treatment, patients frequently develop resistance and relapse. Thus, new anticancer agents 
targeting key signaling nodes are urgently required to improve the survival of breast cancer 
patients. 
 We focused on the most aggressive breast cancer subtypes, TNBCs and HER2-
positive tumors. This work aims at understanding the role of two PTPs, SHP2 and PTPN12, 
in these subtypes of breast cancers. 
 Previous studies suggested that SHP2 might play a positive role in cancer. For 
example, GOF somatic mutations are found in ~35% of juvenile myelomonocytic leukemias 
and at various incidences in other myeloid malignancies, but rarely in solid cancers. SHP2 is 
also activated downstream of oncogenes in gastric carcinoma, anaplastic large cell lymphoma 
and glioblastoma. Although SHP2 mutations in breast cancer were not found, it was shown 
that the gene encoding the SHP2-activating protein GAB2 is amplified and overexpressed in 
10-15% of human breast tumors. In addition, it has been proposed that SHP2 is 
overexpressed both in breast cancer cell lines and infiltrating ductal carcinoma of the breast, 
and that this phosphatase promotes epithelial to mesenchymal transition in breast cancer 
cells. However, none of these studies have addressed the in vivo role of SHP2 in CSCs or in 
tumor maintenance and progression, and the signaling cascades and transcriptional factors 
acting downstream of SHP2 remained ill-defined. We therefore used conditional reverse 
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genetics, 3D cultures and in vivo models complemented by bioinformatic analysis to address 
these important questions. 
 PTPN12 has been previously shown to inhibit cell motility, cytokinesis, and apoptosis 
in several cellular systems. Our collaborators T. Westbrook from The Baylor College of 
Medicine and S. Elledge from Harvard Medical School identified PTPN12 in a screen for 
tumor suppressor genes in human mammary epithelial cells. We tested the effects of PTPN12 
knockdown and/or overexpression of WT and loss of function mutants in the mammary 
epithelial cell line MCF10A grown in 3D cultures, and investigated the role of PTPN12 as a 
tumor suppressor in breast cancer. 
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SUMMARY  
Cancer stem cells (CSCs) influence tumor maintenance, progression and relapse in many 
cancers but the signaling networks controlling these cells remain unknown. We demonstrate a 
fundamental role for protein-tyrosine phosphatase SHP2 in these processes in HER2-positive 
and triple-negative breast cancers, two subtypes associated with a poor prognosis. 
Knockdown of SHP2 eradicated breast CSCs in vitro and in xenografts. SHP2 depletion 
prevented invasion in 3D cultures and progression from in situ to invasive breast cancer in 
vivo. Importantly, SHP2 knockdown in established breast tumors blocked growth and 
reduced metastases. Mechanistically, SHP2 activated stemness-associated transcription 
factors including c-Myc and ZEB1, which resulted in the repression of let-7 microRNA and 
the expression of a set of “SHP2 signature” genes found co-activated in a large subset of 
human primary breast tumors. Taken together, these data show that activation of SHP2 and 
its downstream effectors is required for self-renewal of breast CSCs and for tumor 
maintenance and progression, thus providing new insights into signaling cascades that 
regulate CSCs and a rationale for targeting SHP2 in breast cancer. 
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INTRODUCTION 
Breast cancer is a heterogeneous disease that progresses to metastasis, a fatal hallmark of 
cancer (Nguyen, Bos et al. 2009); and the cellular and biochemical mechanisms orchestrating 
breast tumor maintenance and progression remain largely elusive. The characterization of the 
cellular heterogeneity of the tumor is crucial for the identification of the source of metastases, 
and elucidation of the oncogenic networks of cancer cells is fundamental to the development 
of targeted therapies for this presently incurable disease. 
Tumors, like normal organs, appear hierarchically organized at the cellular level. 
Indeed, normal human and mouse mammary glands contain cells in a dynamic state of 
stemness that are long-lived and self-renewing and that differentiate to all breast cell lineages 
to form a functional gland (Pece, Tosoni et al. ; Kordon and Smith 1998; Shackleton, Vaillant 
et al. 2006; Stingl, Eirew et al. 2006; Sleeman, Kendrick et al. 2007; Raouf, Zhao et al. 2008; 
Visvader 2009; Pece, Tosoni et al. 2010). In the neoplastic breast, recent studies have 
identified subpopulations of cancer cells in a stem-like state that seed and sustain a tumor, 
recapitulating the heterogeneity of the original cancer. This subpopulation of “cancer stem 
cells (CSCs)” or “tumor-initiating cells” (Al-Hajj, Wicha et al. 2003; Dontu, Al-Hajj et al. 
2003; Stingl and Caldas 2007; Polyak and Weinberg 2009; Rosen and Jordan 2009; Visvader 
2009) also plays an important role in metastasis and in resistance to chemo- and radiation 
therapies (Dontu, Al-Hajj et al. 2003; Dean, Fojo et al. 2005; Li, Tiede et al. 2007; Li, Lewis 
et al. 2008; Diehn, Cho et al. 2009). Whilst identification of the Achilles heel of CSCs is of 
paramount clinical importance in the search for therapeutic targets, signaling networks 
controlling CSCs stemness remain ill-defined. 
In cancer, many signaling networks are subverted at the biochemical level (Vogelstein 
and Kinzler 2004; Pawson and Kofler 2009). Most signaling pathways are modulated by 
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reversible protein-tyrosine phosphorylation, which is regulated by protein-tyrosine kinases 
(PTKs) and protein-tyrosine phosphatases (PTPs) (Hunter 2009). Abnormal tyrosine 
phosphorylation underlies various diseases of deregulated growth and differentiation, 
including cancer, and although the roles of several PTKs in breast carcinogenesis have been 
studied extensively (e.g., ErbB2/HER2), elucidation of the roles of specific PTPs in this 
disease has only started recently (Hynes and Lane 2005; Ostman, Hellberg et al. 2006; Tonks 
2006). The first bona fide PTP proto-oncogene was the Src-homology 2 domain-containing 
phosphatase SHP2 (encoded by PTPN11), an ubiquitously expressed PTP that transduces 
mitogenic, pro-survival, cell fate and/or pro-migratory signals from numerous growth factor-, 
cytokine- and extracellular matrix receptors. SHP2 is required for full activation of the 
ERK/MAPK pathway downstream of most receptors; however, its regulation of other 
pathways (e.g., Jak/STAT and PI3K) is cell- and/or receptor-specific (Shi, Yu et al. 2000; 
Chan, Kalaitzidis et al. 2008). Interestingly, gain-of-function (GOF) germline mutations of 
SHP2 cause ~50% of cases of the developmental disorder Noonan syndrome (Tartaglia, 
Mehler et al. 2001). Moreover, mouse genetics, gene silencing and sequencing studies have 
demonstrated a broad role for SHP2 in development, cell fate and tumorigenesis (Grossmann, 
Rosario et al. ; Tartaglia, Mehler et al. 2001; Feng 2007; Chan, Kalaitzidis et al. 2008; 
Grossmann, Rosario et al. 2010). SHP2 null-embryos die peri-implantation and fail to yield 
trophoblast stem cell lines (Yang, Klaman et al. 2006). While SHP2 deficiency increases self-
renewal of murine and human embryonic stem cells (Burdon, Stracey et al. 1999; Wu, Pang 
et al. 2009), it decreases self-renewal in neural stem/progenitor cells and hematopoietic stem 
cells (HSC), suggesting a cell-type specific role of SHP2 in regulating cell fate (Chan, Li et 
al. 2006; Ke, Zhang et al. 2007). Systemic comparative transcriptomics and gene network 
analysis have shown that SHP2 acts as a hub maintaining the stability and connectivity of the 
HSC genetic network (Huang, Hsieh et al. 2008). 
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In malignancies, SHP2 is hyperactivated either by mutations or downstream of 
oncoproteins. GOF somatic mutations are found in ~35% of juvenile myelomonocytic 
leukemias and at various incidences in other myeloid malignancies, but rarely in solid cancers 
(Tartaglia, Niemeyer et al. 2003; Bentires-Alj, Paez et al. 2004; Chan, Kalaitzidis et al. 
2008). SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large 
cell lymphoma and glioblastoma (Chan, Kalaitzidis et al. 2008; Zhan, Counelis et al. 2009). 
Although our previous studies have not found SHP2 mutations in breast cancer, we and 
others have found that the gene encoding the SHP2-activating protein GAB2 is amplified and 
overexpressed in 10-15% of human breast tumors (Bocanegra, Bergamaschi et al. ; Bentires-
Alj, Paez et al. 2004; Bentires-Alj, Gil et al. 2006; Bocanegra, Bergamaschi et al. 2010). It 
has been proposed that SHP2 is overexpressed both in breast cancer cell lines and infiltrating 
ductal carcinoma of the breast, and that this phosphatase promotes epithelial to mesenchymal 
transition in breast cancer cells (Zhou, Coad et al. 2008; Zhou and Agazie 2008). However, 
none of these studies have addressed the in vivo role of SHP2 in CSCs or in tumor 
maintenance and progression, and the signaling cascades and transcriptional factors acting 
downstream of SHP2 remain ill-defined. 
In this present study, using conditional reverse genetics, 3D cultures and in vivo 
models complemented by bioinformatics analysis, we have not only uncovered an SHP2-
dependent positive feedback signaling loop but have also shown that SHP2 regulates breast 
CSCs and is required for breast tumor maintenance and progression. This demonstrates that 
SHP2 is an important target in breast cancer.  
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RESULTS 
SHP2 is necessary for invasion, proliferation and loss of polarity in a 3D culture model 
of invasive breast cancer 
To assess the roles of SHP2 in breast cancer progression, we developed a 3D culture model 
of invasive breast cancer and used inducible small hairpin RNAmiRs (miRs) to deplete SHP2. 
We established that overexpression of HER2 and HER3 caused immortalized but non-
transformed human breast epithelial cells MCF10A to form invasive, unpolarized and 
hyperproliferative 3D structures with a filled lumen (Supplementary Fig. 1a,b). These 
hallmarks are key events in breast cancer initiation and progression (Bissell, Radisky et al. 
2002). Next, we constructed doxycycline (dox)-inducible lentiviral vectors expressing two 
independent SHP2 miRs (SHP2 miR1/2) (Fig. 1a and Supplementary Fig. 2a), generated 
pools of MCF10A-HER2/3 cells expressing the SHP2 miRs and grew them in 3D cultures. 
SHP2 knockdown blocked HER2/3-evoked invasion by 85% (Fig. 1b). To exclude off-target 
effects, we rescued MCF10A-HER2/3 cell-invasiveness by expressing a non-targetable SHP2 
cDNA (Rescue) in cells expressing SHP2 miR2 (Fig. 1a, b and Supplementary Fig. 2a), 
thereby confirming that SHP2 depletion blocks invasiveness in MCF10A-HER2/3 cells. 
To examine other markers in SHP2-depleted MCF10A-HER2/3 cells, we stained for 
the proliferation marker Ki67, the apical Golgi marker GM130 and the basal marker laminin-
5 (Debnath, Mills et al. 2002) in MCF10A-HER2/3 cells expressing CTRL or SHP2 miRs. 
SHP2 inhibition prevented the hyperproliferative, unpolarized and filled-lumen phenotypes of 
MCF10A-HER2/3 in 3D cultures (Supplementary Fig. 2b). Thus, SHP2 is required not only 
for invasiveness but also for hyperproliferation, luminal filling and loss of cell polarity. 
 
Results  
 
 
34 
 
SHP2 promotes the transition from in situ to invasive carcinoma in vivo 
Ductal carcinoma in situ (DCIS), in which cancer cells remain within the milk duct, is 
believed to be the precursor of invasive ductal carcinoma (IDC), the most common type of 
breast cancer (Allred, Wu et al. 2008), yet the signaling networks underlying this transition 
remain ill-defined. To determine the effect of SHP2 knockdown on the transition from DCIS 
to IDC, we used the human-in-mouse intraductal transplantation model (Behbod, Kittrell et 
al. 2009). The onset of DCIS was detected 10 days after intraductal injection of pools of the 
human breast cancer cell line BT474 expressing GFP and CTRL or SHP2 miR1 (Fig. 1c,d 
and Supplementary Fig. 2c), at which point we treated mice with dox for 54 days. Whereas 
CTRL cells invaded the surrounding stroma, indicating progression from DCIS to IDC (Fig. 
1d-f), SHP2 miR1 cells did not progress to invasive carcinoma (Fig. 1d-f). These results 
show that SHP2 is fundamental for breast cancer progression from DCIS to IDC and suggest 
that targeting SHP2 could be useful for blocking breast tumor progression. 
 
SHP2 is essential for tumor maintenance 
The roles of SHP2 in breast tumor growth and progression in vivo are unknown. To test 
whether SHP2 is required for tumor maintenance, we used dox-inducible miRs to deplete 
SHP2 after overt tumor development (Fig. 2a). Pools of three HER2-positive (BT474, 
SKBR3 and MCF10A-NeuNT) and two triple-negative (SUM159 and SUM1315) breast 
cancer cell lines expressing either CTRL or SHP2 miRs were injected orthotopically into 
mammary fat pads of immunodeficient mice. In the absence of dox, tumor growth was not 
affected in SHP2 miR tumors (Supplementary Fig. 3a). Dox treatment dramatically blocked 
the growth of xenografts expressing SHP2 miRs. In contrast, dox administered when tumors 
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from CTRL or SHP2 miRs cells were palpable did not affect the growth of tumors expressing 
CTRL miR or SHP2 miR2 rescued with exogenous SHP2 (Fig. 2b,c). We quantified this 
effect in terms of tumor volume, area and weight (Fig. 2b,c and Supplementary Fig. 3b,c). 
These results show that SHP2 expression is absolutely required for the growth and 
maintenance of established HER2-positive and triple-negative tumors, two breast cancer 
subtypes associated with a poor prognosis. 
At the end of the above experiment, we confirmed that SHP2 expression levels 
remained lower in xenografts of cells expressing SHP2 miRs than in CTRL miR 
(Supplementary Fig. 3d). Immunohistochemical analysis of Ki67 revealed a decrease in 
proliferation in tumors lacking SHP2 (Fig. 2d), while staining for CD31 showed no 
differences in microvessel density. Thus, in addition to its role in promoting proliferation ex 
vivo (Supplementary Fig. 2b), SHP2 also increased proliferation in vivo. Altogether, our 
results show that SHP2 increases cell proliferation and is required for the growth and 
maintenance of two aggressive breast tumor subtypes. 
 
SHP2 promotes metastases 
Given our observations that SHP2 increases invasion ex vivo and in vivo and that this 
phosphatase is required for tumor maintenance in vivo, we asked whether SHP2 knockdown 
in breast tumors also reduces their metastatic capacity. To mimic the neoadjuvant setting 
when patients are treated prior to tumor removal, mice bearing BT474 CTRL or SHP2 miR1 
xenografts were dox-treated for 30 days, tumors were removed and the mice were monitored 
for a further 16 weeks without dox before lung metastases were quantified (Fig. 2e). H&E 
and HER2 staining of the lungs showed that SHP2 knockdown reduced the metastatic 
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capacity of BT474 tumors. Remarkably, the mean number of metastases per mouse was ~4 
times less in the absence of SHP2 than in CTRL (Fig. 2f). These observations demonstrate 
that knockdown of SHP2 in the primary tumor decreased lung metastases. 
 
SHP2 is required for the maintenance and tumor-seeding ability of CSCs 
The role of SHP2 in the maintenance of breast CSCs is unknown. We addressed this question 
using different assays, initially with the tumorsphere-formation assay in which CSCs form 
floating spherical colonies when grown in non-adherent conditions (Dontu, Abdallah et al. 
2003; Ponti, Costa et al. 2005). We measured the tumorsphere-formation efficiency of HER2-
positive and triple-negative breast cancer cell lines in the presence or absence of SHP2 (Fig. 
3a top panels). To assess whether SHP2 controls self-renewal of CSCs, the primary 
tumorspheres were dissociated into single cells and reseeded. Interestingly, the ratio of the 
number of secondary and primary tumorspheres was lower upon SHP2 knockdown than in 
the control, showing that SHP2 depletion decreases self-renewal capacity of CSCs in the 
tested models (Fig. 3a bottom panels). This suggests that SHP2 knockdown reduces self-
renewal of breast CSCs of both HER2-positive and triple-negative tumors. 
Second, we examined CSCs distribution in the presence or absence of SHP2 by 
analyzing the expression of the cell-surface markers CD44 and CD24, as the 
CD44high/CD24low cell population has been shown to be enriched in breast CSCs (Al-Hajj, 
Wicha et al. 2003). HER2/HER3 co-overexpression in MCF10A cells increased the number 
of CD44high/CD24low cells in vitro. Interestingly, knockdown of SHP2 depleted the population 
of CSCs in MCF10A-HER2/3 cells (Fig. 2b,c and Supplementary Fig. 4a,b). We also 
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observed a decrease in the number of CD44high/CD24low cells when we depleted SHP2 in the 
triple-negative breast cancer cells SUM159 (Supplementary Fig. 4c,d). 
Third, to assess directly the effects of SHP2 on the tumor-seeding capacity of breast 
CSCs in vivo, we assayed the ability of human cancer cells to seed tumors or to grow as 
tumorspheres following SHP2 knockdown in xenografts. We isolated single cells from 
tumors with or without SHP2 and either transplanted them in mice at serial dilutions or grew 
them as tumorspheres in the absence of dox (Fig. 3d). Notably, we found that whereas CTRL 
cells efficiently seeded new tumors, deletion of SHP2 in vivo strongly impaired both 
tumorsphere formation and tumor seeding capacity (Fig. 3e,f and Supplementary Fig. 4e). 
The fact that neither mice transplanted with cells, nor the cells grown as tumorspheres were 
treated with dox, indicated that depletion of CSCs upon knockdown of SHP2 happened in 
vivo during dox treatment of the primary tumors. These data indicate a strong requirement for 
SHP2 in the maintenance of breast CSCs in vitro and in vivo. 
 
SHP2 effects on stemness and tumor progression are dependent on activation of the 
ERK pathway  
We next sought to define the biochemical pathways whose activity in breast cancer in vivo 
requires SHP2. Screening for changes in phosphorylation upon SHP2 knockdown in tumors 
using a reverse-phase protein array (RPA) revealed a decrease in phosphorylation of several 
signaling molecules (Fig. 4a and Supplementary Fig. 5a). Immunoblotting of tumor lysates 
confirmed the decrease in phosphorylation of ERK5, ERK1/2, AKT, PLCγ, EGFR and HER2 
(Supplementary Fig. 5b). To distinguish tumor-specific changes in phospho-proteins from 
changes in the mouse stroma, we also analyzed protein phosphorylation in lysates from 
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BT474 tumorspheres. SHP2 deletion dramatically reduced the phosphorylation of ERK5 and 
to a lesser extent of ERK1/2, PLCγ, AKT, EGFR and HER2 (Fig. 4b). Consistently, we also 
observed reduced phosphorylation of ERK5 and ERK1/2 in MCF10A-HER2/3 tumorspheres 
upon knockdown of SHP2 (Supplementary Fig. 5c).  
We then used two independent shRNAs to knockdown ERK5 (ERK5 sh1 and sh2) 
and measured the tumorsphere-formation efficiency of BT474 and MCF10A-HER2/3 cells in 
the presence (CTRL vector) or absence of ERK5. Knockdown of ERK5 reduced tumorsphere 
formation (~30% fewer primary and secondary tumorspheres in ERK5 shRNA cells than in 
CTRL cells) but did not affect self-renewal (Fig. 4c and Supplementary Fig. 5d). These 
results show that ERK5 depletion is not sufficient to phenocopy the effect of SHP2 loss on 
CSCs. Interestingly, upon ERK5 knockdown, BT474 and MCF10A-HER2/3 tumorspheres 
expressed higher levels of active ERK1/2, suggesting that phosphorylation of ERK1/2 may 
compensate for ERK5 loss (Fig. 4d and Supplementary Fig. 5d). We next combined ERK5 
depletion with pharmacological inhibition of ERK1/2 using PD184352. Consistent with 
previous observations (Mody, Leitch et al. 2001), we found that PD184352 specifically 
inhibited ERK1/2 activation at 1 µM and both ERK1/2 and ERK5 activation at 10 µM 
(Supplementary Fig. 5e). Knockdown of ERK5 and treatment of BT474 and MCF10A-
HER2/3 tumorspheres with PD184352 at 1 µM, or treatment with 10 µM PD184352 that 
abrogates activation of both ERK5 and ERK1/2, reduced tumorsphere-formation efficiency 
and self-renewal similar to SHP2 knockdown (Fig. 4e and Supplementary Fig. 5e,f). To 
assess whether inhibition of both ERK1/2 and ERK5 is required for mimicking the effect of 
SHP2 knockdown on CSCs, we treated BT474 and MCF10A-HER2/3 tumorspheres with 
PD184352 at 1 µM, which inhibits ERK1/2 but not ERK5, and found this to dramatically 
reduce tumorsphere formation and self-renewal, recapitulating the effect of SHP2 knockdown 
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(Fig. 4e and Supplementary Fig. 5e,f). These results suggest that SHP2 action on CSCs is 
predominantly dependent on ERK1/2 activation. 
 To further investigate the effects of SHP2-evoked activation of ERK5 and ERK1/2 on 
the number of CSC, we examined CSC distribution in MCF10A-HER2/3 cells lacking ERK5 
and/or treated with PD184352 by measuring the proportion of CD44high/CD24low cells. ERK5 
depletion decreased the CD44high/CD24low cell population by ~35%. Similar to the results of 
the tumorsphere assay, simultaneous inhibition of ERK5 and ERK1/2, or ERK1/2 inhibition 
alone, led to complete depletion of the CD44high/CD24low population (Fig. 4f and 
Supplementary Fig. 5g), exactly as we observed upon SHP2 knockdown (Fig. 3b,c). These 
results show that although ERK5 is hyperactivated in the presence of SHP2, it contributes 
only partially to the role of SHP2 in CSCs, and that SHP2 increases CSCs self-renewal 
predominantly by activating ERK1/2. 
We then investigated whether inactivation of ERK1/2 and/or ERK5 affects the 
invasiveness of MCF10A-HER2/3 cells grown in 3D cultures. ERK5 knockdown in 
MCF10A-HER2/3 cells decreased invasion by ~20%. Notably, the inhibition of ERK1/2 
alone or in combination with ERK5 inactivation completely blocked HER2/3-evoked 
invasion (Fig. 4g).  
 Altogether, our data show that the requirement for SHP2 in self-renewal of breast 
CSCs and tumor progression is predominantly due to SHP2-evoked activation of ERK1/2. 
 
SHP2 increases the activity of stemness-associated transcription factors that repress let-
7 miRNA and increase stemness and invasion of breast tumors 
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The effect of SHP2 on gene expression in cancer has not been examined. To address this, we 
analyzed the gene expression profiles of BT474 CTRL and SHP2 miRs tumors after 30 days 
of dox and identified 180 downregulated genes, referred to as the “SHP2 signature” (Fig. 5a 
and Supplementary Table 1). Gene ontology analysis of the signature revealed enrichment 
in development-associated genes, mainly of the HOX family (Supplementary Fig. 6a,b). To 
identify the transcription factors whose activity is responsible for the observed changes, we 
used a computational method (Suzuki, Forrest et al. 2009) to model global gene expression 
patterns in terms of genome-wide predictions of transcription factor binding sites. This 
analysis identified 10 transcription regulators that are inferred to cause significant 
downregulation of their targets upon SHP2 inactivation (Fig. 5b). Among these transcription 
factors is ZEB1, a zinc finger E-box-binding homeobox 1 that was shown to induce EMT 
(Wellner, Schubert et al. 2009). Consistently, ZEB1 was downregulated in microarrays of 
BT474 tumors lacking SHP2 (Supplementary Table 1). Analysis of RNA from BT474 and 
SUM159 tumors by real-time PCR confirmed that ZEB1 expression was repressed upon 
SHP2 knockdown (Fig. 5c). The repression of ZEB1 was accompanied by downregulation of 
the EMT markers Fibronectin1, Vimentin and N-cadherin (Supplementary Fig. 7), 
indicating a role for SHP2 in EMT in vivo. To assess the functional role of ZEB1 downstream 
of SHP2, we generated pools of MCF10A-HER2/3 cells expressing inducible ZEB1 miR 
(Supplementary Fig. 8a). Knockdown of ZEB1 dramatically reduced invasion in MCF10A-
HER2/3 cells grown in 3D cultures (Fig. 5d). Moreover, ZEB1 depletion reduced the self-
renewal of MCF10A-HER2/3 cells (Fig. 5e), although not to the same extent as depletion of 
SHP2 (Fig. 3a). These data indicate that ZEB1 acts downstream of SHP2 in promoting 
invasion and stemness and suggest that additional mediators are required for the effect of 
SHP2 on self-renewal capacity of CSCs. 
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To address this question, we analyzed transcriptome changes upon SHP2 knockdown 
in vivo with the Ingenuity resource. This analysis revealed that SHP2 knockdown strongly 
affected genes belonging to the c-Myc network (Supplementary Fig. 8b), confirming that c-
Myc transcriptional activity is reduced upon SHP2 knockdown in vivo (Fig. 5b). Moreover, 
the expression of the known c-Myc target LIN28B (Chang, Zeitels et al. 2009), a suppressor 
of miRNA biogenesis, was decreased in microarrays from tumors lacking SHP2 
(Supplementary Table 1). These observations prompted us to dissect the role of c-Myc and 
LIN28B downstream of SHP2 in CSCs. First, we quantified the expression of LIN28B by 
real-time PCR in BT474 and SUM159 tumors, and confirmed that it was transcriptionally 
repressed upon SHP2 knockdown in both models (Fig. 5f). LIN28B has been shown 
previously to suppress the biogenesis of the let-7 miRNA (Viswanathan, Daley et al. 2008; 
Chang, Zeitels et al. 2009; Iliopoulos, Hirsch et al. 2009). Consistently, we observed that 20 
genes among the “SHP2 signature” genes were predicted let-7 targets (Supplementary 
Table 2), the majority of which are tightly associated with the c-Myc pathway 
(Supplementary Fig. 8c). To avoid cross-detection of stromal mouse let-7 miRNA present in 
the tumors, we analyzed its expression in MCF10A-HER2/3 cells grown in 3D cultures in the 
presence or absence of SHP2. Remarkably, we found increased biogenesis of mature let-7a 
and let-7b in the absence of SHP2 in these cells (Fig. 5g). Consistently, whole gene 
expression analysis of MCF10A-HER2/3 cells grown in 3D cultures or xenografts of BT474 
cells showed a stronger decrease in the expression of RNAs encoding predicted let-7 target 
genes than other genes in the absence of SHP2 (Fig. 5h). We further confirmed the 
downregulation, at the protein level, of the let-7 targets RAS and c-Myc in tumors lacking 
SHP2 (Fig. 5i). 
Next, we assessed whether the expression levels of ZEB1 and LIN28B are dependent 
on activation of ERK1/2. Treatment with PD184352 showed that ERK1/2 inhibition reduced 
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the expression of ZEB1 and LIN28B in both SUM159 and MCF10A-HER2/3 cells (Fig. 5j 
and Supplementary Fig. 8d). These data suggest that the effects of SHP2 on ZEB1 and 
LIN28B expression are mediated by ERK1/2. 
Our findings suggest that SHP2 activation of ERK1/2 increases the expression of c-
Myc and LIN28B in breast cancer. To test this model directly, we asked whether restoring the 
expression of c-Myc or LIN28B rescues the effects of SHP2 knockdown. Notably, expression 
of c-Myc restored expression of LIN28B in MCF10A-HER2/3 cells lacking SHP2 
(Supplementary Fig. 8e). Consistently, expression of either c-Myc or LIN28B restored 
invasion and self-renewal of CSCs in MCF10A-HER2/3 cells lacking SHP2 (Fig. 5k,l). 
In summary, we show that SHP2 is required for stemness and invasion of breast 
tumors. Our data demonstrate that SHP2 promotes ERKs activation, causing upregulation of 
ZEB1 and c-Myc-dependent expression of LIN28B, which leads to repression of let-7 
miRNA and overexpression of let-7 target genes including RAS (Fig. 5m). These data 
identify a key feed forward signaling loop required for the maintenance of breast CSCs and 
invasiveness of breast tumors. 
 
SHP2 is expressed and active in a large subset of primary breast tumors  
SHP2 has been previously found expressed in a large number of breast tumors (Zhou, Coad et 
al. 2008), although its expression in normal tissue and its activity in breast cancer patients are 
still unclear. We first examined the expression of SHP2 in normal breast, primary tumors and 
in breast cancer cell lines. We found high levels of SHP2 expression in ~88% of breast 
tumors, but no consistent changes in SHP2 expression between normal and neoplastic tissue 
(Fig. 6a,b and Supplementary Fig. 9a,b). Moreover, SHP2 expression levels did not 
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significantly correlate with any tumor histotype or clinicopathological parameter 
(Supplementary Table 3). These results suggest that SHP2 activation by oncogenes rather 
than SHP2 overexpression determines its roles in breast tumorigenesis. 
 We then used the “SHP2 signature” genes as a readout for SHP2 activation. To assess 
whether expression of the “SHP2 signature” could be used to stratify patients with breast 
cancer, we asked whether the genes from this signature are co-overexpressed in human breast 
tumors. In four independent publicly available datasets, we found that the “SHP2 signature” 
genes are co-regulated and cluster the patients into two groups: one with downregulation 
(group 1) and the other with overexpression (group 2) of the “SHP2 signature” genes. 
Notably, the clear split into “SHP2 signature” low- and high-expression groups was hardly 
ever observed in 10,000 randomly-selected gene groups of the same size (Fig. 6c and 
Supplementary Fig 10). 
We next grouped the data from the four datasets and found that ~55% of all primary 
breast cancers overexpress the “SHP2 signature” genes (Fig. 6d). Strikingly, analysis of two 
of these datasets for which the molecular subtypes were reported showed that the “SHP2 
signature” was high more frequently in triple-negative breast cancers (Fig. 6e), a subtype 
characterized by poor outcome and lack of efficient therapy and thought to be enriched in 
CSCs (Stingl and Caldas 2007; Nakshatri, Srour et al. 2009). 
Taken together, our findings indicate that the “SHP2 signature” genes are 
overexpressed in ~55% of human primary breast tumors, particularly those of the triple-
negative subtype. Importantly, these data suggest that, of all breast cancer subtypes, SHP2 
inhibition might be very effective in patients bearing tumors with high “SHP2 signature” 
genes and might prove particularly effective in triple-negative breast cancer, a currently 
incurable disease. 
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DISCUSSION 
Recent studies have demonstrated the importance of CSCs in breast cancer (Al-Hajj, Wicha 
et al. 2003; Dontu, Al-Hajj et al. 2003; Li, Tiede et al. 2007; Stingl and Caldas 2007; Li, 
Lewis et al. 2008). The signaling networks that govern CSCs remain ill-defined, however, 
and their delineation should pave the way for development of targeted, potentially curative 
cancer therapies. In this study, we provide new insights into the multiple roles of SHP2 in 
cancer. We found that SHP2 increases self-renewal of breast CSCs and is required for breast 
tumor maintenance and progression, demonstrating that SHP2 is a high quality target in 
human breast cancer. 
Evidence that SHP2 increases self-renewal of breast CSCs is shown by several in 
vitro and in vivo models. Knockdown of SHP2 in vitro reduced the proportion of the 
CD44high/CD24low population and decreased tumorsphere-forming efficiency. In several 
different in vivo models, SHP2 knockdown inhibited tumor growth, reduced tumorsphere-
forming efficiency of the cancer cells and dramatically decreased their capacity to seed new 
tumors when transplanted back at limiting dilutions in mice. Evidence for SHP2 requirement 
for breast tumor maintenance and progression comes from our in vivo and 3D culture 
experiments. First, SHP2 knockdown blocked the growth of established breast tumors and 
decreased the number of lung metastases. SHP2 depletion in invasive 3D cultures also 
reduced proliferation and prevented loss of polarity, two critical steps in the oncogenic 
process (Bissell, Radisky et al. 2002; Zhan, Rosenberg et al. 2008), further supporting a role 
for SHP2 in tumor maintenance and progression. Third, knockdown of SHP2 prevented 
invasion in 3D cultures and blocked the transition from DCIS to IDC in a human-in-mouse 
intraductal transplantation model, supporting a role of SHP2 in tumor progression. 
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It was reported recently that induction of an invasive phenotype in normal or 
neoplastic mammary epithelial cell populations increases the number of cells with CSC-like 
properties, suggesting a functional overlap between the invasion phenotype and the state of 
stemness (Mani, Guo et al. 2008). In line with this concept, CSCs are thought to be 
responsible for metastases (Li, Tiede et al. 2007). Our observations that SHP2 regulates CSCs 
and EMT, mediates the progression from DCIS to IDC and promotes metastatic spread 
suggest that SHP2 acts as a molecular hub for these fundamental phenomena. 
Mechanistically, we found that the effects of SHP2 on self-renewal of CSC and 
invasion of breast cancer cells require ERK pathway activation. Further, we show that SHP2 
activation of ERK1/2 induces expression of the transcription factors ZEB1 and c-Myc, the 
latter mediating increase in LIN28B expression. Notably, the EMT-activator ZEB1 has been 
previously suggested to increase stemness in pancreatic and colorectal cancers (Wellner, 
Schubert et al. 2009). Moreover, LIN28B, an RNA-binding protein and a marker of 
undifferentiated human embryonic stem cells (Richards, Tan et al. 2004), promoted c-Myc-
mediated proliferation and invasion in several cancer models (Chang, Zeitels et al. 2009; 
Wang, Chen et al. 2011). In our studies, c-Myc-induced LIN28B expression repressed let-7 
miRNA leading to overexpression of let-7 targets, including RAS and other regulators of 
stemness (Johnson, Grosshans et al. 2005; Iliopoulos, Hirsch et al. 2009). These findings 
uncover a novel mechanism of ERK regulation by SHP2 and identify an SHP2-dependent 
positive feedback loop required for the maintenance of CSC and for the invasiveness of 
breast cancer cells. 
Importantly, our work has led to the discovery of an “SHP2 signature”, a set of genes 
that we found to be co-overexpressed in ~55% of human primary breast tumors. This 
signature reflects the existence of an SHP2-driven gene network, mainly controlled by c-Myc 
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and ZEB1 activity, and capable of maintaining stemness and invasiveness of breast tumors. 
Notably, the SHP2 signature genes are co-overexpressed in ~55% of all breast tumors and 
more frequently in triple-negative breast cancers, an aggressive subtype that lacks efficient 
therapies and is thought to be enriched in CSCs (Stingl and Caldas 2007; Nakshatri, Srour et 
al. 2009). These results suggest that inhibiting SHP2 might be particularly effective in human 
triple-negative breast cancer, specially the ones recently found to be dependent on active 
RTKs (Sun, Aceto et al. 2011), that require SHP2 for full activation of ERK (Chan, 
Kalaitzidis et al. 2008). 
As SHP2 has been shown to act downstream of most growth factor and cytokine 
receptors, targeting SHP2 might be therapeutic in other cancers in which SHP2 is 
hyperactivated, e.g., downstream of the cytotoxin-associated antigen A (CagA) encoded by 
virulent H. pylori strains in gastric carcinoma, of the fusion protein NPM-ALK in anaplastic 
large cell lymphoma, and of EGFRvIII in glioma (Chan, Kalaitzidis et al. 2008). Our findings 
warrant experiments to address whether SHP2 also regulates CSCs, tumor maintenance and 
progression in these malignancies. 
 In summary, we have shown that knockdown of SHP2 depletes the breast CSC-
population and inhibits breast cancer maintenance and progression. These findings reveal a 
fundamental SHP2-dependent positive feedback loop regulating CSCs and reinforce the need 
for developing selective inhibitors of SHP2 for treating aggressive malignancies. 
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FIGURE LEGENDS  
Fig. 1. SHP2 promotes invasion, proliferation and loss of polarity in 3D cultures and in 
vivo. (a) Dox treatment of MCF10A-HER2/3 cells deleted SHP2 in cells expressing SHP2 
miR1 and 2 (90.5% and 91.1%, respectively), but not in cells expressing firefly (CTRL) miR 
or in cells expressing SHP2 cDNA (Rescue) or SHP2 miR2, which targets the 3’ UTR. 
Immunoblot showing expression of SHP2, HER2, HER3 and ERK2 (loading control) in the 
presence (+) or absence (-) of dox. (b) SHP2 knockdown decreased the percentage of 
HER2/3-evoked invasive structures (9% versus 94% in CTRL). Representative phase contrast 
images of MCF10A-HER2/3 cells grown in 3D culture for 20 days and expressing the 
indicated miRs. The bar graph shows the percentage of invasive structures. Results represent 
means ±SEM from five independent experiments; **P<0.0001. (c) Schematic of DCIS onset 
following injection of cells into the primary mouse mammary duct of immunodeficient mice. 
BT474-GFP cells formed DCIS-like lesions 10 days (DCIS Onset) after intraductal injection. 
The miR was activated by treating the mice with dox at the onset of DCIS. (d,e) 
Representative images of whole-mount (d), H&E-stained, GFP-stained and Keratin18-stained 
(e) mammary glands at DCIS onset (top) and after 54 days of treatment with dox (bottom) 
(n=6). DAPI (blue) stained the nuclei. IDC is seen in the presence (bottom left) but not in the 
absence of SHP2 (bottom right). (f) Bar graph showing the mean percentage of mammary 
glands with IDC ±SEM (n=6, *P<0.05). 
Fig. 2. SHP2 is required for tumor maintenance, growth and progression to lung 
metastases. (a) Schematic of the experiment. Cells were injected orthotopically and the mice 
after tumors became palpable were treated continuously with dox to express the miRs. (b, c) 
Tumor growth curves of HER2-positive (b) and triple-negative (c) breast cancer cell lines in 
the presence or absence of SHP2 showing the mean tumor volume (mm3) ±SEM (BT474 
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n=15, SKBR3 n=10, MCF10A-NeuNT n=8, SUM159 n=10, SUM1315 n=9; *P<0.0005, 
**P<0.0001). (d) SHP2 knockdown reduced proliferation. Representative images of H&E-, 
Ki67- and CD31-stained sections of BT474 tumors expressing CTRL or SHP2 miR1 
dissected after 30 days of treatment with dox. Note the decrease in number of mitoses (from 
21/mm2 to 12/mm2) without any sign of necrosis and the increased presence of mature 
collagen (arrows) upon knockdown of SHP2. Immunostaining for Ki67 showed a twofold 
decrease in proliferation in the absence of SHP2. Immunostaining for CD31 revealed no 
differences in microvessel density in the presence or absence of SHP2. The bar graphs show 
the percentage of Ki67- or CD31-positive cells ±SEM (n=8, **P<0.00002) (right). (e) 
Schematic of the lung metastases study. Mice were injected with 106 BT474 cells expressing 
CTRL or SHP2 miR1 and treated with dox for 30 days after the tumors became palpable. The 
primary tumors were then dissected and the mice kept alive without dox for a further 16 
weeks, after which the lungs were analyzed for the presence of metastases. (f) SHP2 
knockdown after overt tumor development reduced the metastatic capacity of BT474 tumors. 
Representative H&E- and HER2-stained histological sections of lungs from mice bearing 
BT474-CTRL or BT474-SHP2 miR1 tumors as indicated. HER2 staining identifies BT474 
foci specifically. Metastases were found in 3 out of 4 animals in the control group and in 4 
out of 8 animals bearing tumors lacking SHP2. The bar graph shows the mean number of 
metastases per animal ±SEM (n=3 in the CTRL group and n=4 in the SHP2 miR1 group; 
*P<0.04). 
Fig. 3. SHP2 maintains the cancer stem cell population in vitro and in vivo. (a) Self-
renewal was reduced in the absence of SHP2. Mean tumorsphere formation and self-renewal 
capacities. Results represent means ±SEM from four independent experiments; *P<0.003, 
**P<0.0008. (b) Representative flow cytometry dot plots showing that HER2/HER3 
increased the CD44high/CD24low subpopulation (green rectangle) in MCF10A cells (left 
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panels). Knockdown of SHP2 decreased the CD44high/CD24low subpopulation. Dot plots of 
CD44/CD24 expression in MCF10A-HER2/3 cells expressing CTRL or SHP2 miR and 
treated with dox for 7 days (right panels). Only RFPhigh cells corresponding to high miR 
expression were counted (Supplementary Fig. 4a). (c) Mean percentage of CD44high/CD24low 
cells in MCF10A cells. Results represent means ±SEM from four independent experiments; 
**P=0.0001. (d) Schematic of the approach used to assess the requirement for SHP2 of CSCs 
in vivo. Mice bearing tumors expressing CTRL or SHP2 miR were treated with dox in vivo. 
Single cells were then generated from the tumors and were either transplanted as serial 
dilutions or seeded for the tumorspheres assay without dox. (e) SHP2 knockdown in 
xenografts reduced the tumorsphere-forming capacity of BT474 cells. Representative images 
of tumorspheres are shown. The bar graph shows the mean number of tumorspheres/104 cells 
±SEM from four independent experiments; **P<0.00001. (f) Limiting dilution 
transplantations show that SHP2 knockdown in xenografts reduced the tumor-formation 
ability of BT474, SUM159 and SUM1315 cells. The transplanted mice were kept without 
dox for 8 weeks, after which the number of mice with tumors was counted; P=2.1x10-9 for 
BT474, P=3.3x10-6 for SUM159 and P=0.0015 for SUM1315 calculated by Poisson test. 
Fig. 4. SHP2 promotion of breast CSCs self-renewal and tumor progression is 
dependent on the ERK pathway. (a) RPA analysis of BT474 tumors treated with dox for 30 
days. Array spot images of three dilutions of lysates from tumors. (b) Immunoblot of lysates 
from BT474 primary tumorspheres in the presence or absence of SHP2. The bar graph shows 
the percentage of normalized protein ±SEM (n=3). (c) ERK5 knockdown partially reduces 
the tumorsphere-forming capacity but does not affect self-renewal of BT474 cells. Bar graphs 
showing self-renewal capacities and the mean number of BT474 tumorspheres/104 cells 
±SEM (n=3); **P<0.004. (d) Immunoblot of lysates from BT474 primary tumorspheres in 
the presence or absence of ERK5 (n=3). (e) Inhibition of ERK1/2 activity alone (1 µM 
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PD184352) or in combination with ERK5 inactivation (1 µM PD184352 and ERK5 shRNA, 
or 10 µM PD184352 alone) decreases BT474 tumorsphere-formation efficiency and self-
renewal. The bar graph shows self-renewal capacities and the mean number of BT474 
tumorspheres/104 cells ±SEM (n=3); *P<0.001, **P<0.0008. (f) Mean percentage of the 
CD44high/CD24low population in MCF10A-HER2/3 cells in the presence or absence of ERK5 
and/or treated with PD184352 for 7 days. Results represent means ±SEM (n=3); *P<0.005, 
**P<5x10-7. (g) The bar graph shows the percentage of invasive structures of MCF10A-
HER2/3 cells grown in 3D culture for 15 days in the presence or absence of ERK5 and/or 
treated with PD184352. Results represent means ±SEM (n=4); *P<0.05, **P<0.003. 
Fig. 5. SHP2 increases the activity of key transcription factors and represses let-7 
microRNA, enhancing invasion and self-renewal of CSCs. (a) Plot of the gene expression 
contrast in BT474 SHP2 miR1–CTRL miR tumors versus SHP2 miR2–CTRL miR tumors. 
The green line circles genes of the SHP2 signature. (b) Table showing the MARA mean 
activity scores (±SD) of 10 transcription factors whose activity was reduced upon SHP2 
knockdown. “P down” values show for each factor the probability of a decreased activity in 
SHP2 miRs compared with CTRL miR samples. (c) Quantitative Real-Time PCR of ZEB1. 
Bar graph showing the percentage of ZEB1 expression in BT474 and SUM159 tumors in the 
presence or absence of SHP2. Results represent means ±SEM (n=3); *P<0.029, **P<0.018. 
(d) Bar graph showing the mean percentage of invasive structures of MCF10A-HER2/3 
grown in 3D cultures for 15 days in the presence or absence of ZEB1 ±SEM (n=3); 
**P<0.01. (e) Bar graphs showing the self-renewal capacities and the mean number of 
MCF10A-HER2/3 tumorspheres/104 cells in the presence or absence of ZEB1 ±SEM (n=3); 
*P<0.05. (f) Quantitative Real-Time PCR of LIN28B. Bar graph showing the percentage of 
LIN28B expression in BT474 and SUM159 tumors in the presence or absence of SHP2. 
Results represent means ±SEM (n=3); *P<0.03, **P<0.02. (g) Quantitative Real-Time PCR 
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on mature let-7a and let-7b miRNAs. The bar graph shows the mean percentage of let-7a and 
let-7b expression in MCF10A-HER2/3 cells grown in 3D cultures for 15 days in the presence 
or absence of SHP2 ±SEM (n=3); *P<0.04. (h) Downregulation of let-7 target genes in the 
absence of SHP2. Curves showing the relative frequency (density) of genes that are not 
targeted by let-7 (non-target), genes that are predicted let-7 targets (let-7 targets), and genes 
that are the 100 most likely let-7 targets (top 100 let-7 targets) according to TargetScan 5.1 
resource (www.targetscan.org) upon SHP2 knockdown in MCF10A-HER2/3 cells grown in 
3D cultures (3D cultures) or in BT474 tumors (in vivo). P values are shown in the plot area. 
(i) Immunoblot showing the expression of SHP2, P-ERK, ERK and the let-7 targets c-Myc 
and RAS in lysates from BT474 tumors treated with dox for 30 days. (j) Quantitative Real-
Time PCR of ZEB1 and LIN28B. Bar graph showing the mean percentage of ZEB1 and 
LIN28B expression in SUM159 cells upon treatment with 1 µM PD184352 for 7 days ±SEM 
(n=3); *P<0.016. (k) Bar graph showing the percentage of invasive structures of MCF10A-
HER2/3 cells grown in 3D cultures for 15 days in the presence or absence of SHP2 and 
expressing a c-Myc or LIN28B rescue. Results represent means ±SEM (n=3); **P<2.9x10-5. 
(l) Bar graph showing the self-renewal capacities of MCF10A-HER2/3 cells in the presence 
or absence of SHP2 and expressing a c-Myc or LIN28B rescue. Results represent means 
±SEM (n=3); **P<0.0015. (m) Model of the mechanism of action of SHP2 in CSCs: SHP2 
activates the ERK pathway, which in turn promotes ZEB1 transcription and c-Myc-dependent 
LIN28B expression. The expression of LIN28B blocks the processing of let-7, maintaining 
high levels of let-7 target genes including RAS and c-Myc. 
Fig. 6. SHP2 is expressed and active in a large subset of breast cancer patients. (a) 
Representative images of human primary normal breast and breast tumors scoring from 0 to 3 
depending on the abundance of SHP2 expression. (b) Quantification of SHP2 expression in 
human normal and neoplastic breast. (c) Expression heatmap for SHP2 signature genes in 
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human primary breast tumors. Mean expression of each gene is indicated in gray, and 
expression level Z-scores are mapped to colors from red (z=-5.0, below mean) to blue (z=5.0, 
above mean). Genes (rows) and patients (columns) are clustered by expression (see 
Methods), resulting in the patient groups 1 and 2. Expression polarization between the groups 
of patients is shown as a red line for the SHP2 signature against 10,000 randomly-selected 
gene signatures of the same size (bottom); P=0.0001 for the Bos, Wang and Bittner datasets, 
P=0.0002 for the Stockholm dataset. (d) Bar graph showing the percentage of all patients 
(including the Bos, Wang, Bittner and Stockholm datasets) belonging to group 1 (low SHP2 
signature genes, i.e. inactive SHP2) or group 2 (high SHP2 signature genes, i.e. active SHP2). 
(e) Bar graph showing the percentage of group 1 and group 2 patients in each breast cancer 
molecular subtype. Genes of the SHP2 signature are upregulated in all the molecular 
subtypes, but more frequently in the triple-negative tumors; P=6.24x10-7 for the Bittner and 
P=2.02x10-12 for the Stockholm dataset. 
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METHODS 
3D cultures. MCF10A cells were grown and stained as previously described (Bentires-Alj, 
Gil et al. 2006). For experiments with inducible miRs, 500 ng/ml of dox and 10 ng/ml of 
heregulin (Sigma) were added to the medium 2 days after seeding the cells and refreshed 
every 2 days.  
Chemicals and vectors. For the inducible RNAi studies, 97-mer shRNAmiR (miR) were 
obtained from Sigma, PCR-amplified, sequence-confirmed and cloned into the dox-inducible 
lentiviral vector pINDUCER (Meerbrey, Hu et al. 2011). We used 2 miRs targeting SHP2, 
SHP2 miR1 (5’-
TGCTGTTGACAGTGAGCGCGGGCACGAATATACAAATATTTAGTGAAGCCACAG
ATGTAAATATTTGTATATTCGTGCCCTTGCCTACTGCCTCGGA-3’) and SHP2 miR2 
(5’-
TGCTGTTGACAGTGAGCGACCACGTATATTATGTAGTCTATAGTGAAGCCACAGA
TGTATAGACTACATAATATACGTGGGTGCCTACTGCCTCGGA-3’) and miR targeting 
ZEB1 
(5’TGCTGTTGACAGTGAGCGAGCGCAATAACGTTACAAATTATAGTGAAGCCACA
GATGTATAATTTGTAACGTTATTGCGCCTGCCTACTGCCTCGGA-3’). As a control, 
we used an miR targeting firefly luciferase (CTRL miR). Constitutive ERK5 shRNAs were 
obtained from Sigma. Rescue experiments were performed with pMSCV-neo-SHP2-WT, 
pBabe-puro-LIN28B (Addgene) and pSD-94-c-Myc (Duss, Andre et al. 2007). PD184352 
(CI-1040) was purchased from Biovision and the cells were treated with fresh inhibitor every 
2 days. 
Animal experiments. Experiments with SCID-beige mice (Jackson Labs) were carried out 
according to FMI guidelines. For the intraductal transplantation, 50,000 BT474 cells were 
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injected as previously described (Behbod, Kittrell et al. 2009). For the other studies, 106 
BT474, 5x106 SKBR3, 106 MCF10A-NeuNT, 106 SUM159 or 106 SUM1315 cells were 
suspended in a 100-µl mixture of Basement Membrane Matrix Phenol Red-free (BD 
Biosciences) and PBS 1:1 and injected orthotopically. For BT474 cells injections, the mice 
were pre-implanted with a 17-Beta-Estradiol (Sigma) pellet. Expression of miRs was induced 
by dox in the drinking water (2 g/l of dox in a 5% sucrose solution), which was refreshed 
every 48 h. 
Tumorsphere assay. Single cells were seeded on Ultra Low Attachment Plates (Corning) at 
a concentration of 100,000/ml. For experiments with inducible miRs, dox was added at the 
beginning of the tumorsphere assay and refreshed every 2 days. Tumorspheres larger than 50 
µm diameter were counted 7 days after seeding (1° tumorspheres). The primary spheres were 
dissociated with HyQTase and 20,000/ml cells seeded in the presence of dox. The number of 
tumorspheres was counted after 7 days (2° tumorspheres). 
Immunohistochemistry. For TMA studies, paraffin sections from a cohort of 19 normal 
human breast tissues and 354 human breast tumors were stained with SHP2 (1:200) 
antibodies (Santa Cruz) as previously described (Zhou, Coad et al. 2008). For the intraductal 
studies, mouse mammary gland tissue was fixed in MethCarnoy’s (60% methanol, 30% 
chloroform and 10% glacial acetic acid) for 4 h, stained in Carmine-Alum solution, 
embedded in paraffin and stained with hematoxylin and eosin (H&E), anti-GFP (MBL) or 
anti-Keratin18 (Fitzgerald) antibodies. For the other xenograft studies, tumors were fixed in 
Formal Fix solution (Thermo Electro Corporation) for 16 h, embedded in paraffin and stained 
with H&E, anti-Ki67 (Thermo Scientific) or anti-CD31 (Dianova) antibodies. Mouse lungs 
were fixed in Bouin’s fixative, embedded in paraffin and stained with H&E or anti-HER2 
(Dako) antibodies. 
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FACS analysis. MCF10A or SUM159 cells were dissociated with HyQTase and stained with 
a 1:5 dilution of Alexa fluor 647 anti-CD24 and a 1:200 dilution of Alexa fluor 488 anti-
CD44 antibodies (Biolegend). 
Microarray analysis. Total RNA was extracted from tumors with TRIzol reagent 
(Invitrogen). RNA was processed, hybridized to GeneChip Human Gene 1.0 ST arrays 
(Affymetrix, Santa Clara, CA) and scanned according to the manufacturer’s instructions. All 
gene arrays were processed in R (www.r-project.org) using bioconductor and the package 
oligo. Robust multi-array mean (RMA) was performed using the following command: expr 
<- rma(read.celfiles(filenames, pkgname=”pd.hugene.1.0.st.v1”), target=”probeset”). 
Expressions for transcript clusters were calculated by averaging corresponding probeset 
values (using array annotation from Affymetrix).  
The contrast between SHP2 miR1–CTRL miR and SHP2 miR2–CTRL miR 
expressing tumors was plotted and 210 Affymetrix IDs were found to be either upregulated or 
downregulated in both SHP2 miRs-expressing tumors (black asterisks in Fig. 5a). Of these 
210 IDs, 182 had a human gene annotation. 180 genes were downregulated whereas only two 
were upregulated in SHP2 miR1/2 tumors (Supplementary Table 1). The 180 downregulated 
genes were considered to be the “SHP2 signature”. 
Analysis of let-7 target genes from microarray data. Contrasts between SHP2 miRs 
samples – CTRL miR were calculated as described above for both MCF10A-HER2/3 cells 
grown in 3D cultures and BT474 tumors in the presence or absence of SHP2. Using the 
TargetScan 5.1 resource (www.targetscan.org), we defined three groups of expressed genes 
(average log2 expression level greater than 4.0): genes that are not targeted by let-7, genes 
that are predicted let-7 targets and genes that are the 100 most likely let-7 targets sorted by 
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TargetScan scores. For each group of genes, we plotted the relative frequency (density) of 
log2 fold changes induced by SHP2 knockdown. 
Analysis of public microarray data. CEL files were downloaded 
(http://www.ncbi.nlm.nih.gov/geo, accessions: GSE12276 for the Bos dataset (Bos, Zhang et 
al. 2009), GSE2034 for the Wang dataset (Wang, Klijn et al. 2005), GSE1456 for the 
Stockholm dataset (Pawitan, Bjohle et al. 2005) and GSE2109 for the Bittner dataset) and 
normalized using gcrma from R/bioconductor. Probesets were linked to genes using 
Affymetrix annotation and, for genes represented by multiple probesets, those with maximal 
variance across tumors were selected. Genes not clearly detected (mean log2 level below 4.0) 
were removed. For clustering and visualization, Z-scores were calculated from expression 
levels of each gene by subtracting the mean and dividing by the standard deviation. Patients 
were split into two groups by k-means clustering and expression polarization was defined as 
the absolute difference between the mean expression levels over genes and patients in each 
group.  
Motif activity response analysis (MARA). We used MARA (Suzuki, Forrest et al. 2009) to 
model genome-wide gene expression patterns in terms of computationally predicted 
transcription factor binding sites. We calculated the means and standard errors of the 
activities of over 200 human regulatory motifs in the CTRL, SHP2 miR1 and SHP2 miR2 
samples, identifying those motifs that were consistently downregulated in both SHP2 miR1 
and SHP2 miR2 samples. 
Immunoblotting and Reverse-Phase Protein Array (RPA). Total protein lysates for 
immunoblotting were obtained using L-buffer (2.5% SDS, Tris-HCl 250 mM pH 7.4). RPA 
was performed as previously described (Voshol, Ehrat et al. 2009). For immunoblotting, we 
used anti-SHP2, HER3, ERK2, EGFR, PLCγ (Santa Cruz), HER2 (Calbiochem), P-EGFR 
Results  
 
 
58 
 
(Invitrogen), P-HER2, Ras (Millipore), P-PLCγ (Upstate), c-Myc (Sigma), P-ERK1/2, P-
ERK5 and ERK5 (Cell Signaling) antibodies. For RPA, we used anti-SHP2 (Santa Cruz), P-
EGFR, P-MEK3/6 (Invitrogen), P-HER2 (Millipore), P-PDGFRbeta, P-ERK5, P-ERK1/2, P-
p38, P-JNK, P-AKT, P-GSK3 α/β, P-S6, P-mTOR, P-PLCγ, P-STAT1, P-STAT3, P-
βCatenin, P-ACC, P-TUBERIN, and P-PP1a (Cell Signaling) antibodies.  
Quantitative Real-Time PCR. Total RNA was extracted with TRIzol reagent (Invitrogen) 
and used as a template for production of cDNA (Invitrogen). cDNA was used for SYBR-
based quantitative real time PCR for quantification of transcript levels of HOXA5 (F: 5’-
GCTGCAAAACGGGGGAAATAAAG-3’; R: 5’-TTTCCCTCGCAGTTCCATTAGGA-3’), 
HOXA9 (F: 5’-GAGGGGAGGGGACAGAGAGGTAG-3’; R: 5’-
CTCCGCTGCTTTATGTTCCTGCT-3’), HOXA13 (F: 5’-
GGCTCCAAGAAACACCCATTCTG-3’; R: 5’-GCAGTGGGGACAGGTCAGGTAAT-3’), 
HOXB5 (F: 5’-AAAGCCCAACCCCTGCTCTAAAA-3’; R: 5’- 
AGTCGCCGGGAGAGAAAGAAAC-3’), HOXB6 (F: 5’-
CGACTGAGAAAAGGGTTGCTGGT-3’; R: 5’-CAATCGCTGGATTCAACCACTCA-3’), 
HOXB9 (F: 5’-ACGCTTTATCAGGCAGTCGGAAA-3’; R: 5’-
CCTGCTCAACTTCTCAGCCAACA-3’), HOXD10 (F: 5’-
TTCCAGTTTAGAGCCTGCCTTGC-3’; R: 5’-GATGATATATGGGCGGGCACAG-3’), 
HOXD11 (F: 5’-CGGGTGGAAGAGAAATCTGGAAC-3’; R: 5’-
GTCTAAGGACAGTGGGGCAGTCG-3’), HOXD13 (F: 5’-
TTTATAAACGTCCCGCGATGAGC-3’; R: 5’-TAGCCCTCTCTCCCTCTGTGAGC-3’), 
ZEB1 (F: 5’-GCACCTGAAGAGGACCAGAG-3’; R: 5’-TGCATCTGGTGTTCCATTTT-
3’), Fibronectin1 (F: 5’-CAGTGGGAGACCTCGAGAAG-3’; R: 5’-
TCCCTCGGAACATCAGAAAC-3’), Vimentin (F: 5’-GAGAACTTTGCCGTTGAAGC-3’; 
R: 5’-GCTTCCTGTAGGTGGCAATC-3’), N-cadherin (F: 5’-
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ACAGTGGCCACCTACAAAGG-3’; R: 5’-CCGAGATGGGGTTGATAATG-3’) and 
LIN28B (F: 5’-CTGTCAGAGCATCATGCACATG-3’; R: 5’-
GGGTGGCTGTGCAACATTTT-3’). GAPDH (F: 5’-ACCCAGAAGACTGTGGATGG-3’; 
R: 5’-TCTAGACGGCAGGTCAGGTC-3’) and ACTIN (F: 5’-
TTGCCGACAGGATGCAGAA-3’; R: 5’-GCCGATCCACACGGAGTACT-3’) were used 
as loading controls. All the primers were designed to specifically amplify human transcripts. 
Statistical analysis. Paired data were evaluated by Student’s t-test. The transplantation 
frequency analysis was performed using R and the “statmod” package as previously 
described (Shackleton, Vaillant et al. 2006). The single-hit assumption was tested as 
recommended and was not rejected for any dilution series (P>0.05). P values for let-7 target 
genes downregulation were calculated with Wilcoxon rank sum test. P values for observed 
expression polarization were calculated as P=(b+1)/(R+1), where R is the number of 
randomly selected gene groups of the same size as our signature (10,000), and b is the 
number of times that a random gene group produced an expression polarization value equal to 
or greater than the one obtained for our signature. P values for association of patient groups 
with molecular tumor subtypes were calculated using Fisher's exact test. 
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6. DISCUSSION AND OUTLOOK 
 
We found opposing roles for SHP2 and PTPN12 in breast cancer: while SHP2 plays an 
oncogenic role and controls key networks of CSCs, PTPN12 acts as a tumor suppressor and 
constrains the activity of proto-oncogenic RTKs in TNBCs. 
 
6.1 The role of SHP2 in CSCs  
 
Recent studies have demonstrated the importance of CSCs in breast cancer. The signaling 
networks that govern CSCs remain ill-defined, and their delineation should pave the way for 
development of targeted, potentially curative cancer therapies when combined with other 
strategies. We provide new insights into the multiple roles of SHP2 in cancer. We found that 
SHP2 increases self-renewal of breast CSCs and is required for breast tumor maintenance and 
progression, demonstrating that SHP2 is a high quality target in human breast cancer. 
Evidence that SHP2 increases self-renewal of breast CSCs is shown by several in 
vitro and in vivo models. Knockdown of SHP2 in vitro reduced the proportion of the 
CD44high/CD24low population and decreased tumorsphere-forming efficiency. In several in 
vivo models, SHP2 knockdown inhibited tumor maintenance and growth, reduced 
tumorsphere-forming efficiency of the cancer cells and dramatically decreased their capacity 
to seed new tumors when transplanted back at limiting dilutions in mice. These effects were 
accompanied by a blockage of invasion in vivo and in 3D cultures, and decreased metastatic 
ability in vivo.   
 
Discussion and outlook 
 
 
119 
 
 
6.2 SHP2 as a molecular hub linking stemness and EMT  
 
It was reported recently that induction of an invasive phenotype in normal or neoplastic 
mammary epithelial cell populations increases the number of cells with CSC-like properties, 
suggesting a functional overlap between the invasion phenotype and the state of stemness 
(Mani, Guo et al. 2008). In line with this concept, CSCs are thought to be responsible for 
metastases. Our observations that SHP2 regulates CSCs and EMT, mediates the progression 
from DCIS to IDC and promotes metastatic spread suggest that SHP2 acts as a molecular hub 
for these fundamental phenomena. 
 
6.3 Mechanism of action of SHP2 in CSCs 
 
Previously, SHP2 was shown to activate both the ERK and AKT pathways by increasing the 
half-life of the activated form of RAS in breast cancer cells (Zhou and Agazie 2009). This 
was accomplished by dephosphorylating an autophosphorylation site on HER2 that serves as 
a docking platform for the SH2 domains of the RAS GTPase-activating protein (RASGAP). 
The net effect was an increase in the intensity and duration of GTP-RAS levels with the 
overall enhancement of ERK and AKT phosphorylation and cell transformation (Zhou and 
Agazie 2009). In addition, SHP2 has been shown to directly activate the SRC family member 
Fyn, downstream of integrin α6β4, to induce invasiveness of breast cancer cells (Yang, Dutta 
et al. 2010), and to promote anchorage-independent growth via SRC/ERK activation 
downstream of MET/integrinβ4 (Bertotti, Comoglio et al. 2006). 
We found that the effects of SHP2 on self-renewal of CSC and invasion of breast 
cancer cells require ERK pathway activation. Further, we show that SHP2 activation of 
ERK1/2 induces expression of the transcription factors ZEB1 and c-Myc, with c-Myc 
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mediating an increase in the expression of the RNA-binding protein LIN28B. Notably, the 
EMT-activator ZEB1 has been previously suggested to induce stemness in pancreatic and 
colorectal cancers (Wellner, Schubert et al. 2009). Moreover, LIN28B, a marker of 
undifferentiated human embryonic stem cells (Richards, Tan et al. 2004), promoted c-Myc-
mediated proliferation and invasion in several cancer models (Chang, Zeitels et al. 2009; 
Wang, Chen et al. 2011). In our studies, c-Myc-induced LIN28B expression repressed let-7 
miRNA leading to overexpression of let-7 targets, including RAS and other regulators of 
stemness. These findings uncover a novel mechanism of ERK regulation by SHP2 and 
identify an SHP2-dependent positive feedback loop required for the maintenance of CSC and 
for the invasiveness of breast cancer cells. 
 
6.4 The “SHP2 signature” in human breast cancer 
 
Our work has led to the discovery of an “SHP2 signature”, a set of genes that we found to be 
co-overexpressed in ~55% of human primary breast tumors. This signature reflects the 
existence of an SHP2-driven gene network, controlled by key transcription factors (e.g., c-
Myc and ZEB1), and capable of maintaining stemness and invasiveness of breast tumors. 
Notably, the SHP2 signature genes are co-overexpressed in ~55% of all breast tumors and 
more frequently in TNBCs. These results suggest that inhibiting SHP2 might be particularly 
effective in human TNBCs, especially the ones we recently found to be dependent on active 
RTKs (Sun, Aceto et al. 2011). 
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6.5 SHP2 as a targets in breast cancer and in other malignancies 
 
As SHP2 has been shown to activate the ERK pathway downstream of most growth factor 
and cytokine receptors, targeting SHP2 might be therapeutic in other cancers in which SHP2 
is hyperactivated, e.g., downstream of the cytotoxin-associated antigen A (CagA) encoded by 
virulent H. pylori strains in gastric carcinoma, of the fusion protein NPM-ALK in anaplastic 
large cell lymphoma, and of EGFRvIII in glioma. Our findings warrant experiments to 
address whether SHP2 also regulates CSCs, tumor maintenance and progression in these 
malignancies.  
Taken together, these findings reveal a fundamental SHP2-dependent positive 
feedback loop regulating CSCs. The facts that 1) SHP2 is a critical node required for 
signaling downstream of virtually all RTKs with transforming potential and 2) promotes self-
renewal of CSCs, breast cancer maintenance, invasion and progression to metastasis, make 
this PTP a critical therapeutic target for breast cancer and provide a rationale for the 
development of selective inhibitors of this phosphatase. 
 
6.6 The role of PTPN12 in TNBCs 
 
In collaboration with the Elledge and Westbrook groups, we demonstrate that PTPN12 is a 
potent tumor suppressor in human breast cancer. We find that PTPN12 loss-of-function leads 
to aberrant acinar morphogenesis and cellular transformation in human mammary epithelial 
cells. Importantly, the tyrosine phosphatase activity of PTPN12 is required for suppression of 
cellular transformation. PTPN12 suppresses transformation by interacting with and inhibiting 
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multiple oncogenic tyrosine kinases including HER2, EGFR and PDGFRβ. Moreover, 
PTPN12 function is frequently compromised in primary human TNBCs by inactivating 
mutations or loss of gene expression. Notably, in breast cancer cells exhibiting PTPN12 
deficiency, restoring PTPN12 expression to levels observed in normal mammary epithelial cells 
suppresses proliferation, tumorigenesis and metastasis, suggesting that the malignant behaviour 
of these cancer cells is dependent on PTPN12 dysfunction. Together, these observations strongly 
support the conclusion that PTPN12 is a suppressor of human breast cancer of the TNBC 
subtype. We propose a model in which PTPN12 inactivation leads to HER2/EGFR/PDGFRβ 
hyper-activity and cellular transformation in HER2-negative breast cancers. Importantly, loss 
of PTPN12 renders TNBCs sensitive to RTK inhibitors. Indeed treatment of cancer cells 
lacking PTPN12 with the EGFR/HER2 inhibitor lapatinib and the PDGFRβ inhibitor 
sunitinib reduced tumor growth and increased overall survival. Therefore, our studies warrant 
a closer examination of the status of tyrosine phosphorylation in what has been previously 
considered non-RTK driven diseases. 
 
6.7 Concluding remarks and future directions 
 
Recently, we have witnessed important discoveries on the function of some members of the 
PTP family. Although PTPs were initially thought to exert tumor-suppressive activity 
because of their antagonistic effects on oncogenic PTKs signaling, the emerging notion that 
some PTPs can act as oncogenes has led to their consideration as drug targets. The 
development of potent and selective inhibitors for these enzymes is therefore of great clinical 
importance. 
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6.7.1 SHP2 as a drug target in breast cancer: 
The better characterized example of an oncogenic PTP is the non-transmembrane 
phosphatase SHP2. The activity of SHP2 is required for self-renewal of breast CSCs and for 
promotion of breast cancer maintenance and progression to metastases. These effects are 
mediated via SHP2 activation of the ERK/MAPK pathway and the transcription factors ZEB1 
and c-Myc. These findings should encourage academic institutes and pharmaceutical 
companies to develop selective inhibitors of SHP2. 
These discoveries lead us to explore new directions:  
1) the fact that SHP2 regulates the expression of mature let-7 miRNA (via c-Myc and 
LIN28B), raises the question of whether this phosphatase also regulates the biogenesis or 
activity of other miRNAs. PTPs play very essential roles in eukaryotic systems, and the 
involvement of members of this family in the control of fundamental regulatory elements like 
miRNAs would not be unexpected. 
2) we have preliminary evidences of a nuclear localization of SHP2 in breast cancer 
cell lines. The role of SHP2 in the nucleus is unknown, as well as if its phosphatase activity is 
at all required in this cellular compartment. Our laboratory is currently addressing these 
interesting questions. 
3) the direct substrate(s) of SHP2 in breast cancer is unclear. We performed 
preliminary SHP2-immunoprecipitation experiments followed by mass-spectrometry to 
identify SHP2 binding partners and substrates. Efforts in this direction should provide a direct 
molecular explanation of the observed downstream signaling cascade, eventually provide 
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novel mechanisms of action of this PTP, and potentially identify additional targets for the 
treatment of breast cancer.  
6.7.2 PTPN12 as a tumor suppressor in TNBC: 
PTPN12 is a tumor-suppressor phosphatase which constrains EGFR, HER2 and PDGFRβ in 
breast cells. In the absence of activating mutations or overexpression of oncogenic enzymes 
like EGFR, HER2 or PDGFRβ, loss of PTPN12 leads to hyperactivation of these RTKs. This 
might also be true for other RTKs regulated by other tumor suppressor PTPs. Therefore, this 
concept provides a rational for targeting tyrosine kinases in TNBC and other cancers based 
on their profile of tyrosine phosphatase activity. 
 Finally, the pathophysiological role of the majority of PTPs in breast cancer is poorly 
characterized. Further studies using physiologically relevant models are required to reveal the 
functions of the “PTP-ome” in breast cancer. Given that the design of drugs targeting PTPs 
presents significant technical challenges, including the high polarity that the compounds must 
have to interact with the PTP domain and the consequent poor cell permeability and 
bioavailability, several efforts are currently made to solve these issues. In particular, 
transmembrane PTPs seem to be suitable targets for development of chemical inhibitors or 
antibodies targeting their extracellular domain, while non-transmembrane PTPs require 
specific and cell-permeable chemical inhibitors or antisense-based therapeutics. As further 
progress will be made in understanding the role of PTPs in breast cancer and in defining their 
substrates, new insights into the molecular mechanisms driving tumorigenesis should be 
revealed. This should ultimately lead to the development of new targeted therapies for the 
treatment of cancer. 
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8. ABBREVIATIONS 
 
 
Dox                   doxycycline 
EGF(R)             epidermal growth factor (receptor) 
EMT                 epithelial-to-mesenchymal-transition 
ERK                  extracellular signal-regulated kinase 
ER                    estrogen receptor 
FBS                  fetal bovine serum 
GAPDH            glycerhaldehyde-3-phosphate dehydrogenase 
Gab2                 GRB2-associated binding protein 2 
HER2               epidermal growth factor receptor 2 
HER3               epidermal growth factor receptor 3 
MARA             motif activity response analysis 
miR                  short hairpin RNA miR 
SHP2                Src-homology 2 domain-containing phosphatase 
PDGFRβ          platelet-derived growth factor receptor beta 
PTPN11           protein tyrosine phosphatase non-receptor type 11 
PTPN12           protein tyrosine phosphatase non-receptor type 12 
RPA                 reverse-phase protein array 
TNBC              triple-negative breast cancer 
ZEB1               zinc finger E-box binding homeobox 1 
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